CUMULATIVE INDEX 2001

Volume 30

March	CONGENITAL ADRENAL HYPERPLASIA, pages 1–244
June	ASSESSMENT OF THYROID FUNCTION AND DISEASE, pages 245–528
September	NEUROENDOCRINOLOGY, pages 529–800
December	TYPE 2 DIABETES, pages 801–1094

Note: Page numbers of article titles are in **boldface** type

Acarbose, for type 2 diabetes, with insulin therapy, 967–968
Acetyl-coenzyme A (CoA), in insulin resistance, 810–811, 891
Achilles reflex time, as thyroid function index, 424
Acromegaly, **565–583**
  clinical features of, 566, 568–570
  diagnosis of, 570–571
  differential diagnosis of, 571
  etiology of, 565–566
  growth hormone levels with, 565–566
    treatment goals for, 572, 576, 578
  hyperglycemia associated with, 824
  insulin-like growth factor 1 levels with, 566, 568–569, 571
    treatment goals for, 572, 576, 578
  magnetic resonance imaging of, 571, 578
  morbidity and mortality of, 569–570
    treatment effects on, 571–572
  treatment of, 571–576
    benefits and drawbacks of, 576, 578
    decision-making paradigm for, 576–578
    dopamine agonists, 573–574, 576–577
    goals for, 571–572
    growth hormone receptor antagonists, 576
    radiation, 573, 576–577
    somatostatin receptor ligands, 574–577
    surgical, 572–573, 576–577
ACTH stimulation test, for glucocorticoid-suppressible hyperaldosteronism, 73
  for 11β-hydroxylase deficiency, 66–68
  for 17α-hydroxylase deficiency, 104, 107
  for 21-hydroxylase deficiency, 4, 50
    for stress dosing of hydrocortisone, 54
    in newborns, 17, 48
  for 3β-hydroxysteroid dehydrogenase deficiency, 92–93
Adenomas, aldosterone-producing, glucocorticoid-suppressible hyperaldosteronism versus, 73–74
  follicular thyroid, cytologic diagnosis of, 371, 375
    genetic transition to carcinoma, 502–503
  hyperprolactinemia from. See *Prolactinomas.*
  hypersomatotropism from, 565–566
    surgical resection of, 572–573, 576–577
Adenosine monophosphate-activated protein kinase (AMPK), in type 2 diabetes, exercise-stimulation of, 890–892
Adiposity. See *Body fat.*
Adiposity rebound, with congenital adrenal hyperplasia treatment, 200
Adipsic hypernatremia, 684–687
  clinical characteristics of, 684
  definition of, 684
  differential diagnosis of, 686–687
  etiology of, 684–685
  pathophysiology of, 685–686
  treatment of, 687
Adolescents, congenital adrenal hyperplasia in, gender assignment for, 150, 162
Adrenal crisis, newborn screening for, 23, 28, 220
  symptoms of, 49

Adrenal crisis *(Continued)*
with 21-hydroxylase deficiency, 48–49, 51
Adrenal gland, human immunodeficiency virus infection and, 757–759
in neuroendocrinology. See *Hypothalamic-pituitary-adrenal (HPA) axis.*
in stress response, 696–697, 699, 702
Adrenal hormones. See also *specific hormone.*
circadian variability of, 50, 195
synthesis of, 1–3, 33–35
11β-hydroxylase isozymes in, 62–66
with congenital adrenal hyperplasia, 31–32
Adrenal masses, aldosterone-producing, glucocorticoid-suppressible hyperaldosteronism versus, 73–74
with congenital adrenal hyperplasia, 45–46, 124
Adrenalectomy, for congenital adrenal hyperplasia, for ovulation stimulation, 213
growth and development effects of, 204
Adrenalitis, with human immunodeficiency virus infection, 757
Adrenocortical hyperplasia, anatomic, 45
congenital. See *Congenital adrenal hyperplasia.*
Adrenocorticotropic hormone (ACTH), in congenital adrenal hyperplasia, cognitive function and, 181–182
CYP11B1 transcription regulation by, 66
CYP21 transcription regulation by, 36–37
pathophysiology of, 1–2, 33
treatment issues of, 3, 122, 194
Adrenocorticotropin hormone (ACTH), human immunodeficiency virus infection and, 757–759
hypothalamic amenorrhea and, 619
in Cushing's syndrome, 731, 734, 736–737
differential diagnosis, 738–744
in stress response, 696, 698–699
neuroendocrinology of, 701, 705–706
of body systems, 710, 714–715
Adult screening, for congenital adrenal hyperplasia, 51
for diabetic complications, 834–835, 838–839
for glucocorticoid-suppressible hyperaldosteronism, 73
for thyroid disease, 251–255
Adults, congenital adrenal hyperplasia in, gender reassignment with, 162
growth and development with, height outcomes, 197, 199–204
treatment considerations of, 124, 127
screening tests for, 51, 73
Aerobic capacity (MVO_2), growth hormone supplements and, 661
with energy deficit, 615
Aerobic exercise, for type 2 diabetes. See *Exercise.*
Afferent system, in energy balance regulation, 766–770
ghrelin, 766–768
insulin, 766–768
integration with central processing unit, 773–775
leptin, 766–767, 769–770
Aging, neuroendocrinology of, in men, **647–669**
combined interventions for, 663–664
gonadal axis and, 648–655
overview of, 647–648, 664–665
somatotropic axis and, 655–663
in women, **631–646**
gonadal steroid feedback response, 639–642
hypothalamic function changes, 632–636
neuroendocrine changes, 632
ovarian changes, 632
overview of, 631–632, 642
pituitary function changes, 636–639
type 2 diabetes and, 804
Agouti-related protein, in energy balance regulation, 772
AIDS. See *Human immunodeficiency virus (HIV) infection.*
AIDS wasting syndrome, 759–760
Albumin, in free thyroid hormone measurement, 265–266
acquired changes in, 268, 273–274, 278
during pregnancy, 276–278
Albumin excretion rate (AER), urinary, in diabetic nephropathy, 837–839
screening guidelines for, 838–839
specific studies on, 842–843, 848–851
Aldosterone, secretion rate determination, for replacement, 196–197
synthesis of, 1–3, 33–35
11β-hydroxylase isozymes in, 62–66
21-hydroxylase deficiency and, 48–50
3β-hydroxysteroid dehydrogenase deficiency and, 83
in glucocorticoid-suppressible hyperaldosteronism, 72–76
with congenital adrenal hyperplasia, 32–33
growth and development effects of, 194
Aldosterone-producing adenomas, glucocorticoid-suppressible hyperaldosteronism versus, 73–74

Aldosterone synthase deficiency, in congenital adrenal hyperplasia, clinical presentation of, 69–71
diagnosis of, 70–71
molecular genetics of, 69–71
pathophysiology of, 32, 70
type I versus type II, 70, 72
Allopregnanolone, hypothalamic amenorrhea and, 619
Alpha-glucosidase inhibitors, for diabetic hyperglycemia, cardiovascular risk factors and, 922
insulin resistance syndrome and, 921
mechanism of actions, 912, 914, 919
side effects of, 923, 925
Ambiguous genitalia. See *Genitalia virilization.*
Amenorrhea, as reproductive stress response, 715
definitions of, 612
from environmental stress. See *Hypothalamic amenorrhea.*
American Academy of Pediatrics, newborn screening recommendations of, 19–20
American Diabetes Association (ADA), diabetes mellitus criteria of, 858–859, 898
Amino acid substitutions, in 11α-hydroxylase/17,20-lyase deficiency, 111–112
5-Aminoimidazole–4-carboxamide ribonucleoside (AICAR), in type 2 diabetes, exercise-stimulation of, 891–892
Amiodarone, thyroid scintiscan interference by, 299
thyroid-stimulating hormone levels and, 251, 256
Amygdala, in stress response, 697, 701, 706–707
Amylin analogue, with insulin therapy, for type 2 diabetes, 976–977
Analogue insulin preparations, 974–976
human preparations versus, 943–944
Analogue tracers, for free thyroid hormone measurement, 272
anomalous protein binding of, 273–274
Anaplastic thyroid carcinoma, cytologic diagnosis of, 372
incidence of, 502
management of, 374–375
Androgen(s), brain masculinization role of, 156, 160, 208–209
neural mechanisms for, 183–185
growth hormone and, in puberty, 530–532
in stress response, 714–715
learning disabilities and, 175–176
placental aromatization of, female fetus development and, 209–212, 222
prenatal, cognitive function and, 183
gender identity and, 156–157, 159
gestational circulation patterns of, 213, 222
Androgen deficiency, in congenital adrenal hyperplasia, intersex abnormalities with, 139, 141–142
of aging males (ADAM), 649. See also *Andropause.*
with human immunodeficiency virus infection, 750–755
as adaptive versus maladaptive response, 751
pathophysiology of, 750–751
poor disease outcome correlation of, 751–752
replacement adverse effects of, 754
replacement effects of, 752–754
replacement recommendations for, 755
Androgen excess, in congenital adrenal hyperplasia, 1–3, 31, 33
as treatment problem, 122–124
corticotropin-releasing hormone antagonists for, 130–131
genotype/phenotype correlation of, 40–43, 49–50
intersex abnormalities with, 142–143
intra-adrenal blockade of, 127
maternal, female fetus development and, 209–212
gestational suppression guidelines for, 216–219, 222
peripheral blockade of, 124–127
signs of, 61, 123
short stature and, 203
spatial abilities and, 178–181
with 11β-hydroxylase deficiency, 67
Androgen supplementation, for andropause, 648
clinical trials of, 652–653
growth hormone combined with, 663–664
side effects of, 654–655
with human immunodeficiency virus infection, adverse effects of, 754
effects of, 752–754
recommendations for, 755
Androgen-to-estrogen conversion blockers, for congenital adrenal hyperplasia, 203–204
Andropause, androgen supplementation for, clinical trials of, 652–653
growth hormone combined with, 663–664
side effects of, 654–655
neuroendocrinology of, 648–655
clinical consequences of, 650–651
epidemiology of, 649
overview of, 647–649, 664–665
physiology of, 649–650

Androstenedione, in congenital adrenal hyperplasia, growth and development effects of, 194, 197, 202
placental aromatization of, female fetus development and, 209–212
gestational management of, 218–219
in steroidogenesis, 34–35
Angina, with coronary heart disease, diabetes mellitus and, 863–864, 983
silent, 865–1033
Angiography, for coronary heart disease, with diabetes mellitus, 866
Angioplasty, for coronary heart disease, with diabetes mellitus, 866
Angiotensin-converting enzyme (ACE) inhibitors, fibrinolytic activity and, 1020–1021
for diabetic microvascular complications, cardiomyopathy, 1039
coronary heart disease, 870
endothelial dysfunction and, 991–992
nephropathy, 839–840
meta-analyses of studies on, 848–851
Angiotensin II, *CYP11B2* expression and, 66
Angiotensin receptor blockade (ARB), for diabetic nephropathy, 840, 848
8-Anilinonaphthalene sulfonic acid, in free thyroid hormone measurement, 269
Anorexia nervosa, hypothalamic amenorrhea with, 616–618
Antiandrogens, for congenital adrenal hyperplasia, action mechanisms of, 125–127
growth and development effects of, 199, 203–204
Antibiotics, for hyperglycemic hyperosmolar syndrome, 819, 822
Anticonvulsants, thyroid-stimulating hormone levels and, 256
thyroxine-binding globulin impact of, 280
Antidiuretic hormone (ADH), **671–694**. See also *Arginine vasopressin (AVP)*.
disorders of, 676–692. See also *specific disorder*.
distribution and clearance of, 675
interaction with thirst, 675–676
normal physiology of, 671–675
regulation of salt and water balance, 675–676
syndrome of inappropriate (SIADH), 687–692
Antihyperglycemic agents. See *Insulin therapy; Oral antihyperglycemic agents*.
Antihypertensive drugs, for diabetic nephropathy, 839–840
for 11β-hydroxylase deficiency, 68
hyperglycemia associated with, 819, 826
Antimicrosomal assays, for thyroid autoantibodies, 320
Antioxidants, in type 2 diabetes, for dyslipidemia, 1005
for oxidative stress, 895–897, 992
Antithrombin (AT), in intrinsic coagulation system, exercise impact on, 1017
with type 2 diabetes, 1012–1013, 1015–1016
Antithyroid drugs, pregnancy impact of, 323–324
thyroid scintiscan interference by, 294, 299–300
APC gene, as follicular thyroid cancer marker, 504
Appetite, as hyperthyroid symptom, 418
during stress response, 707–708
in energy balance regulation, afferent, 766, 768–769
central processing of, 767, 770–775
efferent, 776–779
Arginine tests, for growth hormone deficiency, 550–551
Arginine vasopressin (AVP), **671–694**
disorders of, 676–692
adipsic hypernatremia, 684–687
diabetes insipidus, 676–684
syndrome of inappropriate antidiuretic hormone, 687–692
distribution and clearance of, 675
in stress response, 698, 701, 705
normal physiology of, 671–675
biologic action, 672
biosynthesis, 671–672
chemistry and anatomy, 671–672
secretion regulation, 672–675
regulation of salt and water balance, 675–676
Aromatase, in steroidogenesis, 34–35
placental activity of, female fetus virilization and, 209–212
short stature and, 203
Aromatase inhibitors, for congenital adrenal hyperplasia, 126–127
Arrhythmias. See *Cardiac arrhythmias*.
Arterial compliance, hypertension and, in diabetes mellitus, 990–991
Arteriolar dilatation, for diabetic nephropathy, 840
Arthropathy, with hypersomatotropism, 568
Aspirin, for platelet inhibition, in type 2 diabetes, 1021–1024
thyroxine-binding globulin impact of, 280
Assay(s), for androgen levels, 750
for congenital adrenal hyperplasia, in newborns, 16, 19, 47–48, 217–219
for free thyroid hormone measurement, commercial free T_4 methods, 271–273

evaluation of T_4 methods, 274–276
evolution of, 267, 269–270, 285
validity impairment factors of T_4 methods, 273–275
for growth hormone disorders, 530, 536, 551
for hyperprolactinemia, 589, 591
for hypersomatotropism, 571
for thyroglobulin measurement, 429–432
overcoming limitations of, 436–437
triumphs and tribulations of, 434–436
for thyroid autoantibodies, evolution of, 315, 320–321
for thyroid-stimulating hormone levels, drugs affecting, 255–256
evolution of, 245–246, 249–251, 255
Atherogenic dyslipidemia, in diabetes mellitus, 999–1000
Athletes. See *Women athletes.*
Atorvastatin, for dyslipidemia, with diabetes mellitus, 872, 1005–1007
ATP channels, potassium, insulin sensitivity and, 827
oral antihyperglycemic agents and, 913, 924–925
Atrial fibrillation, with coronary heart disease, diabetes mellitus and, 867
Autoantibodies, thyroid, **315–337**. See also *Thyroid autoantibodies.*
Autoimmune response, to stress, 696, 701, 721
Autoimmune thyroiditis, chronic, ultrasonography of, 345–346
hypertrophic versus atrophic, 346
immunobiology of, 315–316, 322, 328
subclinical hypothyroidism in, 327–329
Autonomic nervous system, during stress response, 697–698
Autonomously functioning thyroid nodules (AFTNs), fine-needle aspiration biopsy of, 307–308, 310, 362–363
Autosomal recessive disease(s), congenital adrenal hyperplasia as, 1, 4

Basal metabolic rate, as thyroid function index, 424–425
Behavior, gender-role, with congenital adrenal hyperplasia, 157–158
prenatal androgens impact on, 156–157
Benign intracranial hypertension (BIH), from human growth hormone, 556
Benign thyroid nodules, management of, 375–382
ultrasonography of, 352–354
Beta-adrenergic agonists, for heart failure, in diabetes mellitus, 1039–1040
Beta-adrenergic blockers, for diabetes mellitus, myocardial infarction and, 864–865
nephropathy and, 850
hyperglycemia associated with, 819, 826–827
hyperthyroidism and, 258, 419, 423
Beta-cell function, in diabetes mellitus, 803–804, 883, 898
insulin therapy and, 936–937
Beta-endorphin, hypothalamic amenorrhea and, 619
Betamethasone, for congenital adrenal hyperplasia, with pregnancy, 217, 219
Bile acid sequestrants, for dyslipidemia, with diabetes mellitus, 1006, 1008
Billewicz index, of hypothyroid symptoms, 419–420
Binding proteins, in free thyroid hormone measurement, 265–269
Blood flow, Doppler ultrasonography of, of heart, with thyroid disease, 420–421
of thyroid, 341–342, 345
with disease, 347, 349, 353
Blood glucose, in type 2 diabetes, control of. See *Glycemic control.*
exercise and, 886–890
acute effects, 887
chronic effects, 887–888
molecular effects, 888–890
patient monitoring of, 942, 944–946
Blood pressure control, for diabetic microvascular complications, 847–852
cardiomyopathy, 1038–1039
coronary heart disease, 869–870, 899
nephropathy, 848–851
other studies, 851–852
retinopathy, 847–848, 900
in type 2 diabetes, exercise and, 894–895, 899
Blood spot sample, for newborn screening tests, 15, 20–21
Body composition, amenorrhea and, 612–614, 617
growth hormone deficiency and, 549
in aging men, 658–660
treatment effects on, 553, 663–664
growth hormone supplementation for, 659–660
androgen combined with, 663–664
leptin role in, 617–618
testosterone decline and, 650–651
growth hormone combined with, 663–664
supplementation effects on, 652–653, 753–754
Body fat, AIDS wasting syndrome and, 759–761
amenorrhea and, 612–614, 617
growth hormone deficiency and, 549, 659–660

Body fat *(Continued)*
androgen supplementation and, 663
HIV–1 protease inhibitor redistribution of, 758–759
stress response and, 716
Body mass index (BMI), amenorrhea and, 613–614, 617
hypothalamic obesity and, 775, 777–778
in diabetes mellitus, fibrinolytic activity and, 1018
ketoacidosis and, 823–824
with congenital adrenal hyperplasia treatment, 94, 200
Bone mineral density (BMD), growth hormone deficiency and, 549
treatment effects on, 554–555, 659
hypothalamic amenorrhea and, 618–622
treatment effects on, 622–623
leptin regulation of, 618
subclinical hyperthyroidism impact on, 258
testosterone decline and, 650–651
supplementation effects on, 653
with congenital adrenal hyperplasia treatment, 201–202
Brain imaging techniques, of cognitive functions, sex differences in, 183–185
Brain insults, with congenital adrenal hyperplasia, learning disabilities from, 175–178
neural effects of, 185–186
Brain masculinization, with androgens, 156, 160, 208–209
neural mechanisms for, 183–185
Breast development, with congenital adrenal hyperplasia, 45
Breast milk, sodium content of, 54
Bromocriptine, for hypersomatotropism, 573–574, 577
for prolactin secretion disorders, 593–598
intravaginal administration, 597–598
long-term considerations, 596
mechanism of action, 593–594
pregnancy effects of, 594, 601–604
resistance to, 597
side effects of, 596–597
to reduce hyperprolactinemia, 594
to reduce prolactinoma size, 594–597
pharmacodynamics of, 593–594
side effects of, 596–597
Bulimia, hypothalamic amenorrhea with, 613, 617

Cabergoline, for hyperprolactinemia, 598–600
for hypersomatotropism, 573–574, 577
Calcifications, with goiters, imaging of, 407–408
Calcitonin, as thyroid cancer marker, 366, 392
Calcium channel blockers, for 11β-hydroxylase deficiency, 68
for 17α-hydroxylase deficiency, 115
Caloric requirements, in type 2 diabetes. See *Diet.*
of women athletes, hypothalamic amenorrhea and, 615–617
Captopril, for diabetic microvascular complications, coronary heart disease, 870
nephropathy, 848–850
for heart failure, in diabetes mellitus, 1038
Carbenoxolone, for congenital adrenal hyperplasia, 130
Carbohydrate metabolism, free fatty-acid levels and, 809
growth hormone deficiency and, 548
treatment effects on, 553–554
Carcinomas. See also *specific type.*
androgen supplementation and, 654, 754
from human growth hormone, 556
growth hormone-secreting, 566
with hypersomatotropism, 569
Cardiac arrhythmias, with coronary heart disease, diabetes mellitus and, 867, 899
with thyroid disease, 258, 416
Cardiac contractility, as thyroid function index, 420–422
Cardiac function, as thyroid function index, hyperthyroidism measures, 258, 416, 420–421
hypothyroidism measures, 421–422
growth hormone deficiency and, 548, 553
Cardiomyopathy, in diabetes mellitus, **1031–1046**
angiotensin-converting enzyme inhibitors for, 1039
beta-adrenergic antagonists for, 1039–1040
blood pressue control for, 1038–1039
coronary heart disease with, 866–867
diabetic, 1035–1037
glycemic control for, 1040–1041
heart failure versus, 1032
impact of, 1031–1033
insulin resistance in, 1037–1038
ischemic, 1033–1035
management of, 1038–1041
nonischemic, 1035–1038
oral hypoglycemic agents and, 1040–1041
risk factor modification for, 1038–1039
Cardiovascular disease (CVD), diabetes mellitus and, arterial compliance and, 990–991

dyslipidemia risk factors, 999–1001
ADA categories of, 1001
ADA therapy thresholds for, 1002–1003
insulin therapy and, 939–940
oral antihyperglycemic agents and, 921–922
risk factors for, 867–874, 983–984
Cardiovascular system, androgen supplementation and, 655
growth hormone deficiency and, 547–548
treatment effects on, 553
hypersomatotropism and, 568
Carney syndrome, hypersomatotropism with, 566
Carpal tunnel syndrome, from human growth hormone, 555–556
with hypersomatotropism, 568–569
Carvedilol, for heart failure, in diabetes mellitus, 1040
CD4 cell counts, with human immunodeficiency virus infection, adrenal insufficiency and, 758
androgen deficiency and, 752–753
growth hormone variability and, 760
CD26, as thyroid lesion marker, 388–389
Cell blocks, for thyroid biopsy cytopreparation, 368
Centers for Disease Control and Prevention (CDC), Newborn Screening Quality Assurance Program of, 21
Central hypothyroidism, testing for, thyroid-stimulating hormone limitations in, 252–254
Central nervous system, during stress response, 696–700
neuroendocrinology of, 697, 701–708
Central processing unit (CPU), in energy balance regulation, 767, 770
Agouti-related protein in, 772
CART in, 771–772
human obesity and, 775
integration of peripheral signals, 773–775
melanocortin receptors in, 772–773
neuropeptide Y in, 772
norepinephrine in, 770
POMC/a-MSH in, 771–772
serotonin in, 771
Cerebral hemispheric specialization, sex differences in, 185
Cervical lymph nodes, thyroid cancer metastasis to, fine-needle aspiration biopsy for, 365–366, 449
Children, Cushing's syndrome diagnosis in, 736
growth hormone deficiency in, retesting adults for, 552
with congenital adrenal hyperplasia, gender reassignment of, 161–162
growth and development with, 43–44, 121
Cholesterol, adrenal hormones from, 1–3, 33–35
Cholesterol levels, endothelium-derived vasodilation and, 987
in diabetes mellitus, NCEP guidelines for, 1002, 1008
in type 2 diabetes, ADA categories of, 1001
ADA therapy thresholds for, 1002–1003
atherogenic, 100
coronary heart disease and, 870–873
exercise and, 894–895
oral antihyperglycemic agents and, 911, 921
pharmacologic agents for, 872, 1005–1008
thyroid hormone therapy impact on, 257
Chorionic gonadotropin (hCG) stimulation, sex differentiation and, 140–141
Chromatography, with assays of congenital adrenal hyperplasia, 47
Chromosome mutations, in thyroid cancer, follicular, 502–505
medullary, 494–501
Chromosomes, for sex differentiation, 138–139
in intersex abnormalities, 139–141
Chronic ambulatory peritoneal dialysis (CAPD), for end-stage renal disease, 840
Circadian variability, of adrenocortical hormones, 50, 195
Clinical Laboratory Improvement Amendments of 1988 (CLIS 1988), 21
Clinical symptom scales, for thyroid function, hyperthyroidism, 416–419
hypothyroidism, 419–420
Clitoris, abnormalities of, with congenital adrenal hyperplasia, gender identity and, 158–163
reconstruction of, 144–150
sexual activity and, 164–165
in fetal sex differentiation, 139–141
Clitorophallus, surgical reconstruction of, 144–150, 159
Clomiphene citrate, for infertility, with congenital adrenal hyperplasia, 50, 213, 222
Clopidrogel, for platelet inhibition, in type 2 diabetes, 1024
Clotting factors, in intrinsic coagulation system, with type 2 diabetes, 1012–1013, 1015–1016
Coagulopathy, in diabetes mellitus. See *Procoagulant state.*
Cocaine/amphetamine-regulated transcript (CART), in energy balance regulation, 771–772

Cognitive function, growth hormone
decline and, 658, 660
supplementation effects on, 660–661
with congenital adrenal hyperplasia, **173–192**
ACTH abnormalities and, 181–182
brain insults and, 175–178, 185–186
differential deficits in, 177–178
enhanced intelligence, 174
gender differences in, 46, 178–184
glucocorticoid excess and, 182–183
impaired intelligence, with salt-wasting form, 174–175, 185
learning disabilities, 175–178
nature of, 174–183
neural substrates of, 183–186
in androgen effects, 183–185
owing to disease or treatment, 185–186
prenatal treatment and, 10–11
spatial abilities, 178–181
summary of, 186–188
Colloid, in thyroid biopsy specimens, 368–371
Colon cancer, with hypersomatotropism, 569
Colon polyps, benign, with hypersomatotropism, 569
Color flow Doppler ultrasonography, for thyroid, 341–342, 345
with disease, 347, 349, 353
Coma, with hyperglycemic hyperosmolar syndrome, 818
Computed tomography (CT) scan, for Cushing's syndrome diagnosis, 738, 742
of hyperprolactinemia, 591, 604
of metastatic thyroid cancer, isotope imaging versus, 471, 480, 482, 484, 487–488
of substernal goiters, **401–414**
appearance of, 405–407
decision to use, 409
patient selection for, 409–413
Conduction disorders, with coronary heart disease, diabetes mellitus and, 867
Congenital adrenal hyperplasia (CAH), ACTH in. See *Adrenocorticotropic hormone (ACTH).*
aldosterone synthase deficiency in, 69–72
androgen factors of. See *Androgen deficiency; Androgen excess.*
classical, clinical features of, 43–49
gender and sexuality in, **155–171**
pregnancy outcomes with, 208–221
clinical features of, 31–32
classical, 43–49
nonclassical, 49–52
cognitive function in, **173–192**. See also *Cognitive function.*
diagnosis of, steroid patterns in, 4–5, 33–35
due to 11α-hydroxylase deficiency, 101–116. See also *11α-hydroxylase deficiency.*
due to 11β-hydroxylase deficiency, 1–2, 10, 32–33, 66–69. See also *11β-hydroxylase deficiency.*
due to 21-hydroxylase deficiency, **31–59**. See also *21-hydroxylase deficiency.*
clinical features of, 43–52
genetics of, 35–43
hormone replacement therapy for, 52–54
growth and development with, **193–206**
pathophysiology of, 1, 3–5, 31, 33
due to 3β-hydroxysteroid dehydrogenase deficiency, **81–99**. See also *3β-hydroxysteroid dehydrogenase deficiency.*
forms of, 31–32
gender and sexuality in, **155–171**
gender development with, 156–163
intersex abnormalities of, 138–150
sexual activity with, 164–167
sexual orientation and, 163–164
glucocorticoid-suppressible hyperaldosteronism in, 72–76
growth and development with, adult height outcomes, 124, 128, 197, 199–204
basal steroid imbalances and, 194
bone mineral density, 201–202
in children, 43–44, 121
penile length, 201
prenatal, 199–200, 202
therapeutic considerations of, **124, 127, 193–206**
weight changes, 200
medical treatment of, **121–135**
alternative glucocorticoid formulations or dose schedules, 129–130
corticotropin-releasing hormone antagonist, 130–131
gene therapy as, 131–132
glucocorticoids for, 52–53, 194–196
goals of, 121–122
growth and development monitors with, 197, 199–200
growth hormone for, 128–129
21-hydroxylase deficiency issues in, 122–124
intra-adrenal blockade of androgen, 127
luteinizing hormone-releasing hormone agonist, 128–129
mineralocorticoids for, 54, 196–197
peripheral blockade of androgen and estrogen, 124–127

prenatal, effects on growth, 199–200, 202
stress dosing for, 53–54, 220
molecular genetics of, 5–6
newborn screening for, **15–30**. See also *Newborn screening.*
nonclassical, clinical features of, 49–52
pregnancy outcomes with, 221–222
optimal-gender policy for, 155–156, 159
pathophysiology of, 1–3
pregnancy outcomes with, **207–229**
in classic 21-hydroxylase deficiency, 208–220
in nonclassic forms, 221–222
in other classic forms, 220–221
prenatal treatment of, algorithm for, 6–8
breakthrough in, 6
controversy over, 11
gender development and, 10–11, 156
11β-hydroxylase deficiency in, 10
21-hydroxylase deficiency in, 5–6, 8, 43
New York Hospital-Cornell Medical Center experience with, 8, 10
pathophysiology of, 3–6
steroidogenesis in, 1–3
racial/ethnic prevalence of, genetic analysis of, 1, 3–4, 6, 37
of aldosterone synthase deficiency, 70–71
of 11β-hydroxylase deficiency, 61, 69, 221
of 21-hydroxylase deficiency, 51
of P450c17 enzyme deficiencies, 112–113
with newborn screening, 16–18, 28, 222
salt-preservation with, 4, 31
salt-wasting with, cognitive function and, 174–175, 185
newborn screening for, 16–17, 20–21, 23, 27–28
pregnancy outcomes with, 208–209, 212–215, 217
treatment of, 54
with 21-hydroxylase deficiency, 31, 37, 40, 42, 48–51, 70
with 3β-hydroxysteroid dehydrogenase deficiency, 83–84, 87, 91
surgical treatment of, **137–154**
at adolescence, 150
evolution of, 137–138
in infant, 143–150
intersex abnormalities as indication for, 139–142
perioperative steroid management for, 54, 143–144
sex determination and, 138–139
Congenital hypothyroidism, scintigraphy verification of, 304
thyroglobulin measurements in, 454–455
Congestive heart failure, in diabetes mellitus, with coronary heart disease, 866–867
with oral antihyperglycemic agents, 926–927
Constitutional delay of puberty, as hormonal disorder, 536–538
Continuous subcutaneous insulin infusion (CSII), 968–970
Contrast enhancement, iodinated, of computed tomography, for substernal goiters, 405–407
Core temperature, elevation of, with stress response, 707
Coronary artery bypass grafts (CABG), with diabetes mellitus, 866
Coronary heart disease (CHD), diabetes mellitus and, **857–881**
angina with, 863–864
angiographic procedures for, 866
arrhythmias with, 867
cardiomyopathy with, 866–867
coagulation factors and, 873
congestive heart failure with, 866–867
exercise guidelines for, 899
glycemic control and, 867–869
hypertension and, 869–870
insulin therapy and, 939–940
lipid levels and, 870–873
microalbuminuria and, 869–870
mortality with, 860–863
insulin therapy and, 939–940
myocardial infarction with, 864–865
prevalence, 857–860
renal disease and, 869–870
risk factors for, 867–874
silent ischemia with, 865
total risk-factor burden in, 873–874
Corticosteroids, human immunodeficiency virus infection and, 757–759
inhaled/nasal, Cushing's syndrome from, 737–738
Corticosterone methyloxidase deficiency, clinical presentation of, 69–71
molecular genetics of, 69–71
type I versus type II, 32, 70, 72
Corticotropin (CTH). See *Adrenocorticotropic hormone (ACTH); Pituitary corticotropin.*
Corticotropin-releasing hormone (CRH), hypothalamic amenorrhea and, 616, 619
in congenital adrenal hyperplasia, antagonist therapy for, 130–131
growth and development effects of, 194
pathophysiology of, 33, 52
pregnancy outcomes with, 213
in Cushing's syndrome, 731, 736–737

Corticotropin-releasing hormone (CRH) *(Continued)*
differential diagnosis, 738, 741–744
in stress response, 696, 698, 700
chronic hyperactivation, 717–720
chronic hypoactivation, 720–721
neuroendocrinology of, 701–707
of reproductive axis, 713–715
tissue localization of, 709–711
Corticotropin-releasing hormone antagonist, for congenital adrenal hyperplasia, 130–131
Cortisol, congenital adrenal hyperplasia and, as treatment problem, 122–123, 195
deficiency mechanisms of, 1, 33, 48, 51
growth and development effects of, 194
replacement therapy for, 52–54
elevated levels of. See *Cushing's syndrome.*
human immunodeficiency virus infection and, 758–759
hypothalamic amenorrhea and, 618
in 3β-hydroxysteroid dehydrogenase deficiency, 83
in stress response, 698, 714
late-night serum and salivary, in Cushing's syndrome, 734–736
synthesis of, 1–3, 33–35
diurnal rhythm of, 50, 195
during stress, 51
11β-hydroxylase isozymes in, 62–66
rate determination, for replacement, 195–196
Cortisone acetate, for congenital adrenal hyperplasia, due to 21-hydroxylase deficiency, 53, 195
growth and development effects of, 199, 201–203
perioperative management of, 143–144
with pregnancy, 216, 218
Counseling, with congenital adrenal hyperplasia, on gender assignment, for parents, 160–163
for patients, 162–164
on sexuality issues, 167
preconception (genetic), 47, 52, 216, 222
Creatine kinase, as thyroid function index, 423
Cultural values, gender reassignment and, 162
on sexual orientation, 162–164
Cushing's syndrome, clinical features of, 730–731
cognitive function and, 182–183
diagnosis of, **729–747**
desmopressin stimulation test, 737
dexamethasone-corticotropin-releasing hormone test, 736–737
inhaled/nasal corticosteroids in, 737–738
late-night serum and salivary cortisol, 734–736
low-dose dexamethasone suppression testing, 733–734
urine free cortisol measurement, 731–733
differential diagnosis of, **729–747,** 738
high-dose dexamethasone suppression testing, 739–740
inferior petrosal sinus sampling, 740–743
pituitary magnetic resonance imaging, 743
plasma corticotropin measurement, 738–739
from glucocorticoids, 53, 121
for congenital adrenal hyperplasia, 122–124, 127
hyperglycemia associated with, 825
iatrogenic, owing to inhaled/nasal corticosteroids, 737–738
metabolic syndrome X versus, 729–731
pseudo-Cushing's syndrome versus, 716, 719, 733, 735, 737
stress response versus, 716, 719
Cutaneous lichen amyloidosis, in multiple endocrine neoplasia type 2, genetic basis of, 495
CYP11B1 gene, mutations of, in glucocorticoid-suppressible hyperaldosteronism, 74–75
in 11β-hydroxylase deficiency, 6, 64–66
CYP11B1 isozyme, in adrenal steroid synthesis, 63–64
CYP11B2 gene, expression regulation of, 66
mutations of, in aldosterone synthase deficiency, 69–71
in glucocorticoid-suppressible hyperaldosteronism, 74–75
CYP11B2 isozyme, in adrenal steroid synthesis, 63–64
CYP17 gene, mutations of, in 17α-hydroxylase deficiency, 101, 103
P450c17 deficiencies and, 101–104
CYP21 gene, mutations of, in 11β-hydroxylase deficiency, 64–66
in 21-hydroxylase deficiency, 5, 8, 35–37, 142
phenotype correlation to, 5, 40, 42–43
pregnancy outcomes with, 216, 221–222
transcription regulation mechanisms of, 36–37
CYP21P gene, mutations of, in 21-hydroxylase deficiency, 5, 35–37
prenatal management of, 6, 8
Cystic fluid measurement, for thyroglobulin levels, 450–451

Cysts. See *specific anatomy.*
Cytokines, in type 2 diabetes, 807
Cytologic smears, of thyroid fine-needle aspiration biopsy, diagnostic evaluation of, 369–370
  preparation of, 367–369
  specific disease identification with, 370–372
  subgrouping of suspicious lesions, 383–384
Cytometric DNA measurements, for suspicious thyroid lesions, 384

Daily function/incapacitation, as hyperthyroid symptom, 419
DAX–1 gene, in sex differentiation, 138–139
de Quervain's thyroiditis. See *Subacute thyroiditis.*
Deamino-D-arginine vasopressin (DDAVP), for adipsic hypernatremia, 587
  for Cushing's syndrome diagnosis, 741
  for diabetes insipidus, diagnosis, 679, 681–682
    treatment, 683–684
Death. See *Mortality rate.*
Dehydroepiandrosterone (DHEA), fetal production of, 210
  in human immunodeficiency virus infection, 758
  in 17α-hydroxylase deficiency, 101, 103, 115
  in hypothalamic amenorrhea, 618
  in 3β-hydroxysteroid dehydrogenase deficiency, 83–84, 86, 91–92, 94
  in steroidogenesis, 34–35
  limited diagnostic use of, 48
Deiodinases, thyroxine, thyroid-stimulating hormone levels reflection of, 246–248
Demeclocycline, for syndrome of inappropriate antidiuretic hormone, 692
Deoxycorticosterone (DOC), in 11β-hydroxylase deficiency, 4–5, 66
  in 17α-hydroxylase deficiency, 103–105, 107, 113–115
  in steroidogenesis, 33–35
Depression, melancholic, with chronic stress response, 718–720
  thyroid autoantibodies in, 329
  postnatal, 326–327
Desmopressin stimulation test, for Cushing's syndrome, 737
Dexamethasone, for congenital adrenal hyperplasia, alternative formulations or dose schedules, 129
  due to 17α-hydroxylase deficiency, 115
  due to 21-hydroxylase deficiency, 53–54, 200
  during pregnancy, 8–10, 200, 216–217, 219, 222
  for glucocorticoid-suppressible hyperaldosteronism, 73
  prenatal, for *CYP21* gene mutations, 222
  for 21-hydroxylase deficiency, 6, 8, 200
    at New York Hospital-Cornell Medical Center, 8, 10
    cognitive function and, 183
    follow-up studies on, 10
    gender-role behavior and, 158
    management guidelines for, 216–217, 219
Dexamethasone-corticotropin-releasing hormone test, for Cushing's syndrome, 719, 736–737
Dexamethasone-suppressible hyperaldosteronism, clinical presentation of, 72–74
  genetic analysis of, 74–76
Dexamethasone suppression testing, for Cushing's syndrome, high-dose, 739–740
  low-dose, 733–734
Diabetes Control and Complications Trial (DCCT), 841–844, 868, 909, 941
Diabetes insipidus, 676–684
  acquired, 677–679
  arginine vasopressin role in, 677–682, 684
  causes of, 676–679
  clinical characteristics of, 676
  congenital, 677, 679
  DDAVP for, diagnosis, 679, 681–682
    treatment, 683–684
  definition of, 676
  differential diagnosis of, 680–682
  genetic, 677–679
  nephrogenic, 679–680, 682–683
    with human immunodeficiency virus infection, 761
  pathophysiology of, 679–680
  pituitary, 677, 683
  treatment of, 682–684
  types of, 676–679
Diabetes mellitus (DM). See also *specific type.*
  ADA criteria for, 858–859, 898
  beta-cell function in, 803–804, 883, 898
    insulin therapy and, 936–937
  cardiomyopathy and heart failure in, **1031–1046**
    angiotensin-converting enzyme inhibitors for, 1039
    beta-adrenergic antagonists for, 1039–1040
    blood pressue control for, 1038–1039

Diabetes mellitus (DM) *(Continued)*
coronary heart disease with, 866–867
diabetic, 1035–1037
glycemic control for, 1040–1041
heart failure versus, 1032
impact of, 1031–1033
insulin resistance in, 1037–1038
ischemic, 1033–1035
management of, 1038–1041
nonischemic, 1035–1038
oral hypoglycemic agents and, 1040–1041
risk factor modification for, 1038–1039
cardiovascular disease in, arterial compliance and, 990–991
dyslipidemia risk factors, 999–1003
insulin therapy and, 939–940
oral antihyperglycemic agents and, 921–922
risk factors for, 867–874, 983–984
coronary heart disease and, **857–881**
angina with, 863–864
angiographic procedures for, 866
arrhythmias with, 867
cardiomyopathy with, 866–867
coagulation factors and, 873
congestive heart failure with, 866–867
exercise guidelines for, 899
glycemic control and, 867–869
hypertension and, 869–870
insulin therapy and, 939–940
lipid levels and, 870–873
microalbuminuria and, 869–870
mortality with, 860–863
insulin therapy and, 939–940
myocardial infarction with, 864–865
prevalence, 857–860
renal disease and, 869–870
risk factors for, 867–874
silent ischemia with, 865
total risk-factor burden in, 873–874
dyslipidemia in, **999–1010**
ADA categories of, 1001
ADA therapy thresholds for, 1002–1003
atherogenic, 999–1000
cardiovascular disease and, 870–873, 999–1003
endothelium-derived vasodilation and, 987
exercise and, 894–895
glycemic control effect on, 1004–1005
isolated, 1000
lifestyle modifications for, 1003–1004
metabolic syndrome, 1000–1001, 1008
NCEP guidelines for, 1002, 1008
oral antihyperglycemic agents and, 911, 921–922
pharmacologic therapy for, 1005–1008
risk factors for, 999–1000
hyperglycemia with. See *Diabetic hyperglycemia.*
hypertension in, **983–997**
arterical compliance and, 990–991
control studies on, 847–852, 869–870
coronary heart disease and, 869–870
endothelial dysfunction and, pathophysiology of, 985–990
treatment effects of, 991
epidemiology of, 983–984
hyperglycemia associated with, 819, 826, 839
microvascular complications associated with, 839
pathophysiology of, 984–985
islet-cell antibodies in, 824, 937
metabolic syndrome in, 1000–1001
microvascular complications of, **833–856**
blood pressure control and, 847–852
coronary heart disease as, **857–881**
glycemic control and, 840–847
nephropathy as, 836–840
retinopathy as, 833–836, 900
risk factors and prevention of, 840–852, 939–940
reactive oxygen species in, 984, 986–989
stress response with, 716, 719
type 2. See *Diabetes mellitus type 2.*
Diabetes mellitus type 2, aging and, 804
clinical significance of, 812
definition of, 801
diet in, exercise and, 883–886, 894, 898
endothelial dysfunction in, **983–997**
adverse consequences of, 992
endothelins and, 989–990
exercise and, 895–898
hypertension and, 983–985
treatment effects of, 991
insulin resistance syndrome and, 989
nitric oxide and, 985–986
endothelium-derived and vascular tone, 985
oxidative stress and, 984, 987–989
exercise impact on, 895–897
vasoactive factors of, 985
vasodilation mechanisms of, 986–987
exercise in, **883–987**
background on, 883–886
blood glucose and, 886–890
acute effects, 887
chronic effects, 887–888
molecular effects, 888–890
blood pressure and, 894–895, 899
endothelial function and, 895–898
guidelines for, for prevention, 897–898
with microvascular complications, 900–901
without complications, 898–900
insulin sensitivity and, 892–893
molecular basis of, 893–894

lipids and, 894–895
metabolic effects of, 805–806, 886
signal-transduction molecules and glucose transport, 890–892
vascular reactivity and, 895–897
hyperglycemic crises in, **817–831**
diabetic ketoacidosis, 823–824
endocrinopathies, 824–825
hyperglycemic hyperosmolar syndrome, 817–823
medications resulting in, 825–827
insulin therapy for, **935–982**. See also *Insulin therapy.*
measurement of, 801–802
obesity and, 806–807, 883–884, 898
oral antihyperglycemic agents for, **909–933**. See also *Oral antihyperglycemic agents.*
pathogenesis of, **801–815**
free fatty acid-induced defect in, 802, 805–812
insulin resistance in, 803–804
pregnancy and, 804–805
prevalence of, 857–860, 883–884
procoagulant state in, **1011–1030**
evidence for, 1012–1015
exercise therapy for, 1017–1018
fibrinolytic system, 1013–1014
therapy for, 1016–1025
intrinsic coagulation system, 873, 1012–1013
therapy for, 1015–1016
oral antidiabetic agents for, 1018–1021
platelet function in, 873, 984, 1014–1015
platelet inhibitors for, 1021–1025
vascular thrombosis, 1011–1012
weight loss for, 1018
with coronary heart disease, 873
Diabetic cardiomyopathy, 1035–1037
Diabetic dyslipidemia, 1000
Diabetic hyperglycemia. See also *Diabetes mellitus.*
oral antihyperglycemic agents, **909–933**
cardiovascular risk factors and, 921–922
exercise and, 900
general treatment considerations, 910–911
in combination therapy, 927–929
in Diabetes Control and Complications Trial, 869
in type 2 diabetes, as crisis, **817–831**
control of, 916–919
insulin resistance syndrome and, 919–921
mechanisms of actions, 911–916
side effects of, 923–927
Diabetic ketoacidosis (DKA), in type 2 diabetes, 823–824
Diabetic nephropathy, 836–840
blood pressure control studies for, 848–852
detection of, 838–839
epidemiology, 836–837
glycemic control studies for, nephropathy, 839–847
stage progression of, 837–838
treatment of, 839–840
urinary albumin excretion in, 837–838
Diabetic neuropathy, cardiomyopathy and, 1033–1037
coronary heart disease and, 863–864, 867
exercise and, 900–901
Diabetic retinopathy, blood pressure control studies for, 847–848, 900
classification of, 833–834
detection of, 834–835
epidemiology of, 833, 873
exercise and, 900
glycemic control studies for, 835–836, 841–845
thrombolytic therapy contraindication with, 864
treatment of, 835–836
Diacyl glycerol (DAG), in insulin resistance, 810–812
Dialysis, equilibrium, for free thyroid hormone measurement, 267–268, 272–273, 283
for end-stage renal disease, 840
Diarrhea, as hyperthyroid symptom, 418
Diet, in type 2 diabetes, exercise and, 883–886, 894, 898
fibrinolytic activity and, 1018
for dyslipidemia, 1003
Dietary supplements, thyroid scintiscan interference by, 294, 299
Dihydrotestosterone, in fetal sex differentiation, 158
in steroidogenesis, 33–35, 42
short stature and, 202
Dilution factor, in free thyroid hormone measurement, 273, 275
Diphosphonates, for subclinical hyperthyroidism, 258
Dissociation, in free thyroid hormone measurement, 266–267, 269
Diuretics, for 11β-hydroxylase deficiency, 68
in diabetes mellitus, for heart failure, 1038–1039
hyperglycemia associated with, 819, 826–827
thyroxine-binding globulin impact of, 280–281
Diurnal rhythm, of thyroid-stimulating hormone, 250
DNA measurements, cytometric, for suspicious thyroid lesions, 384

DNA mutations, in congenital adrenal hyperplasia, intersex abnormalities with, 139–141
of glucocorticoid-suppressible hyperaldosteronism, 74–76
with aldosterone synthase deficiency, 69–71
with 11β-hydroxylase deficiency, 68–69
with 21-hydroxylase deficiency, 5–6, 8, 35–40
ethnic differences in, 51–52
heterozygosity of, 42, 51–52
phenotype correlation with, 5, 40–42
with 3β-hydroxysteroid dehydrogenase deficiency, 87–91
in classic versus nonclassic types, 91–94
with P450c17 enzyme deficiencies, 109–113
Dopamine agonists, for hypersomatotropism, 573–574, 576–577
pregnancy and, 594, 601–604
prolactinomas and, 587, 591
as treatment, 593–598
Dopamine antagonists, thyroid-stimulating hormone levels and, 255–256
Dopaminergic agents, thyroid-stimulating hormone levels and, 255, 281
Dopaminergic system, in stress response, 701, 706
prolactin secretion and, 587
Doppler ultrasonography, of heart, with thyroid disease, 420–421
of thyroid, 341–342, 345
with disease, 347, 349, 353
Double-antibody precipitation assays, for newborn screening, of congenital adrenal hyperplasia, 19
Drug(s), hyperglycemia associated with, 825–827
hyperglycemic hyperosmolar syndrome from, 819–820
hyperprolactinemia from, 587–588
thyroid scintiscan interference by, 294, 299
thyroid-stimulating hormone levels impact of, 255–256
during critical illness, 281–282, 284
thyroxine-binding globulin impact of, 267–268
free thyroid hormone levels and, 278–280
Dyslipidemia, in diabetes mellitus, **999–1010**
ADA categories of, 1001
ADA therapy thresholds for, 1002–1003
atherogenic, 999–1000
coronary heart disease and, 870–873
endothelium-derived vasodilation and, 987
exercise and, 894–895
glycemic control effect on, 1004–1005
isolated, 1000
lifestyle modifications for, 1003–1004
metabolic syndrome, 1000–1001, 1008
NCEP guidelines for, 1002, 1008
oral antihyperglycemic agents and, 911, 921
pharmacologic therapy for, 1005–1008
risk factors for, 999–1000

Eating disorders, hypothalamic amenorrhea with, etiology of, 613, 615–618
treatment of, 622–623
with chronic stress response, 719–720
Ectopic thyroid tissue, scintigraphy of, 302–303
ultrasonography of, 344
Efferent system, in energy balance regulation, hypothalamic obesity treatment and, 777–778
integration with central processing unit, 773–775
nucleus tractus solitarius, 767, 776
parasympathetic nervous system, 777
resting expenditure and, 778–779
sympathetic nervous system, 776–777
thermic effect of food, 779
voluntary expenditure and, 779
Ehlers-Danlos syndrome, 35
Electrolyte balance/imbalance. See also *specific electrolyte.*
in hyperglycemic hyperosmolar syndrome, 818–819, 822
oral antihyperglycemic agents and, 924–925
with congenital adrenal hyperplasia. See *Salt-wasting.*
with mineralocorticoid deficiency, 68, 70–71
Emotions, body system manifestations of, 711, 716
psychologic stress and, chronic dysfunction of, 717–721
neuroendocrinology of, 708–709
stress response dysfunction with, 717
End-organ function, subclinical hyperthyroidism impact on, 258–259
End-stage renal disease (ESRD), with diabetes mellitus, 836–839, 984
treatment of, 839–840
Endocrine function. See also *Neuroendocrinology.*
during stress response, 698
with hypersomatotropism, 569

Endocrinopathy(ies), hyperglycemia associated with, 824–825
hyperglycemic hyperosmolar syndrome from, 819–820
Endothelial dysfunction, in type 2 diabetes, **983–997**
adverse consequences of, 992
cardiomyopathy and, 1033, 1035, 1041
endothelins and, 989–990
exercise and, 895–898
hypertension and, 983–985
treatment effects of, 991
insulin resistance syndrome and, 989
nitric oxide and, 985–986
endothelium-derived and vascular tone, 985
oxidative stress and, 984, 987–989
exercise impact on, 895–897
vasoactive factors of, 985
vasodilation mechanisms of, 986–987
Endothelins, in type 2 diabetes, 989–990
Energy balance, behavioral factors of, 765–766
in hypothalamic amenorrhea, 615–617
neuroendocrine regulation of, 766–767, 780
afferent system in, 766–770
central processing in, 770–776
efferent system in, 776–779
Environmental factors, of amenorrhea. See *Hypothalamic amenorrhea.*
of 21-hydroxylase deficiency, 42
Enzyme(s), as thyroid function index, 422–423
defects of, in congenital adrenal hyperplasia, 1–2, 31–32
Enzyme-linked immunosorbent assay (ELISA), for growth hormone disorders, 536
for newborn screening, of congenital adrenal hyperplasia, 16, 19
for thyroglobulin, 431–432, 434–436
Epinephrine, in stress response, 696, 698, 700
Equilibrium dialysis, for free thyroid hormone measurement, 267–268, 272–273, 283
Erotic sensitivity, genital surgery impact on, 164–166
Erythrocytosis, from androgen supplementation, 655, 754
Esophagus, displacement of, with substernal goiter, 402, 407, 409, 413
Estradiol, free thyroid hormone impact of, 277–278
in steroidogenesis, 33–35
with maternal hyperandrogenism, 209–211
Estrogen(s), blockade of, for congenital adrenal hyperplasia, 124–127
fibrinolytic activity and, 1021
for hyperprolactinemia, 600–601
for hypothalamic amenorrhea, 622–623
for subclinical hyperthyroidism, 258
growth hormone and, in puberty, 532–533
in brain differentiation, 158
in placental activity, with maternal hyperandrogenism, 209–211
in stress response, 715
resistance to, short stature and, 203
thyroxine-binding globulin impact of, 267–268, 276
Estrogen deficiency, in aging women, reproductive axis feedback of, 639–642
negative, 639–640
positive, 641–642
Estrogen excess, in congenital adrenal hyperplasia, 33
as treatment problem, 123–124
Estrogen replacement therapy, for congenital adrenal hyperplasia, adult height and, 199
with 17α-hydroxylase deficiency, 114–115
with 3β-hydroxysteroid dehydrogenase deficiency, 95–96
Estrone, in steroidogenesis, 33–35
with maternal hyperandrogenism, 209–211
Ethnic prevalence. See *Racial/ethnic prevalence.*
Eudragit, for congenital adrenal hyperplasia, 129–130
Euglycemic-hyperinsulinemic clamp technique, for insulin resistance measurement, 801–802
EURODIAB Controlled Trial of Lisinopril in Insulin-dependent Diabetes Mellitus (EUCLID), 847–848
Euthyroid sick syndrome, pituitary-thyroid axis in, 254–255
Euthyroidism, during pregnancy, 323, 326
fetal, ultrasonography of, 345
in autoimmune thyroid disease, 327–328
Exendin-4, with insulin therapy, for type 2 diabetes, 977
Exercise, growth hormone supplementation and, 662–663
in energy balance regulation, 779
in type 2 diabetes, **883–987**
background on, 883–886
blood glucose and, 886–890
acute effects, 887
chronic effects, 887–888
molecular effects, 888–890
blood pressure and, 894–895, 899
endothelial function and, 895–898
fibrinolytic activity and, 1017–1018
for dyslipidemia, 1003–1004

Exercise *(Continued)*
guidelines for, for prevention, 897–898
with microvascular complications, 900–901
without complications, 898–900
insulin sensitivity and, 892–893
molecular basis of, 893–894
lipids and, 894–895
metabolic effects of, 805–806, 886
signal-transduction molecules and glucose transport, 890–892
molecular basis of, 888–890
vascular reactivity and, 895–897
reproductive dysfunction from. See *Hypothalamic amenorrhea.*
testosterone replacement and, 753
External insulin pumps, 968–970
Extraction technique, for newborn screening, of congenital adrenal hyperplasia, 18
Extramyocellular triglyceride (EMCL-TG), in insulin resistance, 810
Extrapituitary disease, hypersomatotropism from, pituitary tumors versus, 566, 571
Eye disease, thyroid-associated, autoantibody assays for management of, 324

Familial dysalbuminemic hyperthyroxinemia (FDH), 268
Familial follicular thyroid carcinoma, 504–505
Familial medullary thyroid carcinoma (FMTC), 493–501
Feeding signals. See *Appetite.*
Fertility, congenital adrenal hyperplasia impact on, 44–45, 50, 124, 207
lower rate factors, 208–209, 221
preconception management of, 213, 216, 221
dopamine agonist effects on, 601
Fetal demise, with prenatal treatment, of congenital adrenal hyperplasia, 10–11
Fetal development. See also *Pregnancy outcomes.*
dopamine agonist effects on, 601
maternal thyroid disease and, 257, 323
of thyroid gland, ultrasonography of, 344–345
with congenital adrenal hyperplasia, gender differentiation in. See also *Androgen(s).*
brain development and, 185
genetic basis of, 138–139
prenatal treatment and, 10–11, 156
maternal hyperandrogenism and female fetus, 209–212

Fibric acid derivatives, for dyslipidemia, with diabetes mellitus, 1006–1007
Fibrinogen, in diabetes mellitus, procoagulant state of, 873, 1012–1013
therapy for, 1015–1016
Fibrinolytic system, in type 2 diabetes, 1013–1014
therapy for, 1016–1025
Filter paper form, for newborn screening, 15–16, 20–21
Fine-needle aspiration biopsy (FNAB), of thyroid gland, **361–400**
complications of, 368–369
cytologic diagnosis with, false-negatives in, 373, 377–378, 390
strategies to minimize, 378–382
false-positives in, 375, 388
in nodule management, 373–389
main aspects of, 369–370
sample adequacy for, 369, 380, 390–392
sensitivity, specificity, and accuracy of, 372–373
specific disease identification, 370–372
stain preparation for, 369
diagnostic accuracy of, 372–373
strategies to maximize, 377–382
diagnostic problems of, 389–393
cystic lesions as, 389–390
inadequate sampling as, 369, 380, 390–392
thyroxine suppression trial for, 392–393
for benign lesion management, 375–382
for malignant lesion management, 374–375, 506
for nodules, for management guidance, 373–389, 506
indications for, 306–308, 310, 312, 362–363
palpable versus nonpalpable, 363–365
ultrasound-guided, 353–354, 362, 367, 391
for suspicious lesion management, 382–389
for thyroiditis, 365, 375
increasing relevance of, 361–362, 393–394
indications for, 363–366
cervical lymph node metastases, 365–366, 449
for ectopic tissue, 344
for Graves' disease, 348, 364–365
for incidentalomas, 364–365
for multinodular goiter, 350, 364
nodules as, 306–308, 310, 312, 362–363

nonnodular enlargement, 365
nonpalpable nodules, 363–365
palpable nodules, 363
techniques for, 366–368
aspiration, 366–367
smear preparation and staining, 367–369
ultrasound-guided, 353–354, 362, 367, 391
Flavoprotein antigen, for thyroid-associated eye disease, 324
Florinef, for congenital adrenal hyperplasia, perioperative management of, 143–144
salt-wasting form, 197
Fludrocortisone, for congenital adrenal hyperplasia, 127
adult height and, 199
due to aldosterone synthase deficiency, 71
due to 21-hydroxylase deficiency, 54
for syndrome of inappropriate antidiuretic hormone, 692
Fluid replacement, for adrenal crisis, 49
for hyperglycemic hyperosmolar syndrome, 821–822
for syndrome of inappropriate antidiuretic hormone, 692
Fluid retention, with oral antihyperglycemic agents, 926–927
Fluoro–18-deoxyglucose positron emission tomography (FDG-PET), of metastatic thyroid cancer, 471, 483–485, 488
Flutamide, for congenital adrenal hyperplasia, 126–127
adult height and, 199
Follicle-stimulating hormone (FSH), changes with aging, hypothalamic, 632
pituitary, 636–639
puberty onset and, 530, 534
reproductive feedback response, 639–640
human immunodeficiency virus infection and, 750
Follicular thyroid adenomas, cytologic diagnosis of, 371, 375
genetic transition to carcinoma, 502–503
Follicular thyroid carcinoma (FTC), cytologic diagnosis of, 371, 375
familial/hereditary predisposition to, 504–505
familial non- (FNMTC), 505
incidence of, 502
markers of, 366, 438
as diagnostic or prognostic tool, 505–507
genetic, 502–507
Follicular variant of papillary thyroid cancer (FVPTC), cytology of, 382–383, 388
46 XX Karyotype, in congenital adrenal hyperplasia, gender development with, 155–163
17α-hydroxylase deficiency with, 105, 115
sexual orientation with, 163–164
46 XY Karyotype, in congenital adrenal hyperplasia, 17α-hydroxylase deficiency with, 105, 107, 113–114
intersex abnormalities with, 139–141, 143
Fracture risk, growth hormone deficiency and, 549
Framingham Heart Study, diabetes risk factors in, 873–874
cardiomyopathy and, 1032, 1036
Free a-subunit (FAS), of gonadotropin, changes with aging, hypothalamic, 634–635
pituitary, 636–639
Free fatty acids (FFA), in type 2 diabetes, insulin resistance with, 810–812
location of defect, 808–809
mechanisms of, 802, 805–807, 810
oral antihyperglycemic agents and, 912
Free hormone hypothesis, validity of, 267
Free testosterone index, in aging men, 649
Free thyroid hormone measurement, **265–289**
binding proteins in, 265–267
changes in, 267–269
evolution of, 265–267, 269–270, 285
free T_4 concentration in, critical illness and, 281–283
during replacement therapy, 278
estimation methods of, 266, 270–276
heparin artifact with, 280–281
hypothyroidism and, 278
in premature infants, 282–283
in special circumstances, 276–283
pregnancy and, 276–278
role of, 283–284
thyroid hormone binding competitors and, 278–280
thyroid-stimulating hormone relationship with, 284–285
thyrotoxicosis and, 278
hypothesis validity of, 267
iodothyronine assays for, 265, 269–270
purpose of, 285
thyroid hormone-binding ratio for, 266, 270
estimation of free T_4 concentration for, 271–276
Fundus photography, for diabetic retinopathy, 834–835
Furosemide, thyroxine-binding globulin impact of, 280–281

Gadolinium injection, for magnetic resonance imaging, of goiters, 406, 408
Galectins, as thyroid lesion marker, 387–388
Gamma-amino-butyric acid (GABA), in stress response, 697, 699, 704–705
Gastrointestinal system, oral antihyperglycemic agents and, 925–926
  stress response of, 711–713, 720
Gastroparesis, with hyperglycemic hyperosmolar syndrome, 821–823
GATA 4 gene, in sex differentiation, 138–139
Gemfibrozil, for type 2 diabetes, fibrinolytic activity and, 1020
Gender, in congenital adrenal hyperplasia, **155–171**
  gender development, 10–11, 156–163
  sexual activity and, 164–167
  sexual orientation and, 163–164
Gender assignment. See also *Gender reassignment.*
  quality-of-life issues with, 156, 161–163, 166–167
  with congenital adrenal hyperplasia, at birth, 161
    gender-atypical behavior with, 162–163
    gender identity and, 158–161
    genital examinations and, 167
    parental counseling about, 160–163
    patient counseling with, 162–164
    prenatal ultrasonography for, 219
    sexual activity and, 164–167
    sexual functioning and, 156, 163–164
    sexuality counseling with, 167
    surgical techniques for, 138–139, 144–150
Gender-atypical behavior, with congenital adrenal hyperplasia, 162–163
Gender determination. See *Gender assignment.*
Gender development, growth hormone and, 534–535
  with congenital adrenal hyperplasia, gender assignment in, 158–161
    gender identity in, 156, 158–161
    gender reassignment in, 158–163
    gender-role behavior in, 156–158
    prenatal treatment and, 10–11, 156
Gender dysphoria, with gender change, 159, 162
Gender identity, definition of, 156
  prenatal androgens impact on, 156
  with congenital adrenal hyperplasia, gender assignment and, 158–161
    gender-atypical behavior with, 162–163
    gender reassignment and, 161–163
Gender rearing, ambiguous, 159, 162
Gender reassignment, patient-initiated, 159
  physician-initiated, 161–162
  with congenital adrenal hyperplasia, gender-atypical behavior with, 162–163
    gender identity and, 158–162
    in adolescence and adulthood, 162
    in childhood, 161–162
Gender-role behavior, definition of, 156
  with congenital adrenal hyperplasia, 157–158
Gender-role expectations, gender reassignment and, 159, 162
Gene mutations, in thyroid cancers, follicular, 501–507
    medullary, 493–498, 501
  in thyroid hormone resistance, 248, 268
  in type 2 diabetes, 804
Gene regulation, of thyroglobulin, 430–431
Gene therapy, for congenital adrenal hyperplasia, 131–132
Genetic counseling, for congenital adrenal hyperplasia, 47, 52, 216, 222
Genetic disorders, genetic polymorphism versus, 51
  hypersomatotropism with, 566
Genetic markers, of thyroid neoplasia, **493–513**. See also *specific gene.*
    anaplastic, 504
    follicular epithelium, 502–507
    hereditary medullary, 493–501
    malignant, 366, 392, 437–438, 448
    papillary, 502–503
    RET proto-oncogene as, 493–503, 505
    sporadic medullary, 501
    suspicious, 387–389
Genetic screening, for follicular thyroid cancer, 505–506
  for medullary thyroid cancer, hereditary, 498–499
    false results with, 500–501
  sporadic, 501
Genetics and genetic analysis. See also *specific gene.*
  of congenital adrenal hyperplasia, 4–6, 31–32
    aldosterone synthase deficiency, 69–71
    glucocorticoid-suppressible hyperaldosteronism, 74–76
    11β-hydroxylase deficiency, 5–6, 68–69, 101
    11β-hydroxylase isozymes, 64–66
    21-hydroxylase deficiency, defect analysis in, 5, 35–40
      genotype/phenotype correlation in, 5, 40–42
      heterozygosity in, 42, 51–52
      prenatal applications of, 5–6, 8, 43
    3β-hydroxysteroid dehydrogenase deficiency, 87–91

classic versus nonclassic types, 91–94
3β-hydroxysteroid dehydrogenase isozymes, 84–87
intersex abnormalities and, 139–143
P450c17 enzyme deficiencies, 109–113
of prolactinomas, 590
of sex differentiation, 138–139
of stress response, 698–699
emotions and, 708–709
of type 2 diabetes, 804, 883
population. See also *Racial/ethnic prevalence.*
of congenital adrenal hyperplasia, 1, 3–4, 6, 37
per adult screening, 51
per newborn screening, 16–18, 28
Genital examinations, psychological issues with, 167
Genitalia differentiation, fetal timeframe for, 209
genetic basis of, 138–139
with congenital adrenal hyperplasia, abnormalities of, 138–143. See also *Genitalia virilization.*
ambiguous, newborn screening for, 16–20, 220
with 21-hydroxylase deficiency, 3–4, 33, 42
Genitalia virilization, Prader stages of, 8, 10, 23, 41
gender assignment and, 156, 158–161
with congenital adrenal hyperplasia, 1–4, 6
gender development issues with, 156–163
genetic basis of, 138–143
11β-hydroxylase deficiency and, 67
21-hydroxylase deficiency and, 3–4, 33, 40, 42–45
17α-hydroxylase/17,20-lyase deficiencies and, 105, 113
3β-hydroxysteroid dehydrogenase deficiency and, 83–84, 91–96
newborn screening for, 16, 23, 27–28, 40
prenatal treatment of, 8, 10
sexual activity and, 164–167
sexual orientation with, 163–164
surgical reconstruction of, at adolescence, 150
gender assignment for, 158–163
in infant, 143–150
with maternal hyperandrogenism, 209–212
Genotype and genotyping. See *Genetics and genetic analysis.*
Gestational management, of congenital adrenal hyperplasia, classic forms, 216–221
glucocorticoid replacement for, 216–222
mineralocorticoid replacement for, 217–220
nonclassic forms, 221–222
Ghrelin, in aging men, 655–656, 658
in energy balance regulation, 766–768
GHRP-6 test, for growth hormone deficiency, 551
Glargine insulin, for type 2 diabetes, 944, 975–976
Glomerular filtration rate (GFR), in diabetic nephropathy, 838, 848–850
Glucagon-like peptide analogues, with insulin therapy, for type 2 diabetes, 977
Glucagonoma, hyperglycemia associated with, 825
Glucocorticoid(s), excess of, cognitive function and, 182–183, 186
with congenital adrenal hyperplasia treatment, 124–127
human immunodeficiency virus infection and, 758–759
in stress response, 699, 704, 713
of growth and metabolism, 715–716
suppression of, for congenital adrenal hyperplasia, 3, 124–127
synthesis of, 33–35
thyroid-stimulating hormone levels and, 256, 281
thyroxine-binding globulin impact of, 268
Glucocorticoid-remediable aldosteronism, clinical presentation of, 72–74
genetic analysis of, 74–76
Glucocorticoid replacement therapy, for congenital adrenal hyperplasia, alternative formulations or dose schedules, 129–130
Cushing's syndrome from, 122–124
due to 11β-hydroxylase deficiency, 68
due to 17α-hydroxylase deficiency, 114–115
due to 21-hydroxylase deficiency, 52–53, 122–124
gestational management of, with classic forms, 216–220
with nonclassic form, 221–222
growth effects of, 44, 193–206
modalities for, 194–195
perioperative management of, 54, 143–144
preconception management of, 213, 216
pregnancy outcomes with, 208, 212–215
stress dosing of, 53–54, 220
unresolved problems with, 122–124
for glucocorticoid-suppressible hyperaldosteronism, 73

Glucocorticoid-suppressible hyperaldosteronism, aldosterone-producing adenomas versus, 73–74
clinical presentation of, 72–74
genetic analysis of, 74–76
Gluconeogenesis, with stress response, 716
Glucose, for hyperglycemic hyperosmolar syndrome, 822
serum. See *Blood glucose.*
Glucose sensors, real-time continuous, 945–946
Glucose tolerance test, for diabetes mellitus, 858–859
for insulin resistance, 802
oral, for hypersomatotropism, 571
Glucose transport. See *Glucose uptake.*
Glucose uptake, in type 2 diabetes, exercise-stimulated, 890–892
molecular basis of, 888–890
insulin-stimulated (ISGU), 801–802, 806
free fatty-acid defect with, 808–809
GLUT 4 translocation, in type 2 diabetes, with exercise, 888–890, 892, 894
GLUT carrier proteins, in type 2 diabetes, exercise and, 888–890, 892
Glyburide, for diabetic hyperglycemia, in combination therapy, 927–929
side effects of, 923–925
Glycemic control, for diabetes mellitus. See *Insulin therapy; Oral antihyperglycemic agents.*
for diabetic microvascular complications, 840
cardiomopathy, 1040–1041
cardiovascular disease, 1004–1005
coronary heart disease and, 867–869
exercise and, 886–890
nephropathy, 839–847
renal biospy and transplantation studies, 846–847
retinopathy, 835–836, 841–845
specific studies and trials, 841–846
target levels for, 869
glycosylated hemoglobin in, 841–843, 845
combined therapies and, 927–928, 962
insulin therapy and, 937, 957–960
oral therapies and, 909–910, 917–919
Glycemic index (GI), of foods, 1018
Glycogen synthesis, free fatty-acid levels and, 808–809
Glycolysis, free fatty-acid levels and, 808–809
Glycoprotein IIb/IIIa inhibitors, for platelet inactivation, in type 2 diabetes, 1024–1025
Glycosylated hemoglobin (HbA_{1c}), in glycemic control, 841–843, 845
combined therapies and, 927–928, 962
insulin therapy and, 937, 957–960
oral therapies and, 909–910, 917–919
procoagulant state and, 1013, 1019
Goiters. See also *Graves' disease.*
classification of, 306
fetal, 345
fine-needle aspiration biopsy for, 350, 364, 370–371
incidence of, 401
intrathoracic, 402, 407, 410
mediastinal, 402–405
scintigraphy of, 306–308, 310
simple diffuse versus multinodular, diagnostic approaches to, 345, 350, 370–371
imaging of, 402, 409
substernal. See *Substernal goiters.*
thyroid autoantibodies in, 327–329
thyroid-stimulating hormone suppression for, 253, 257–258, 260
scintigraphy evaluation with, 296, 308, 310
ultrasonography of, 342–343, 345, 350
Gonad(s), masculinized. See *Genitalia virilization.*
sex differentiation of. See *Genitalia differentiation.*
Gonadal axis, human immunodeficiency virus infection and, 750–755
stress response of, 713–715
Gonadal dysgenesis, from androgen deficiency, 141–142
from androgen overexpression, 142–143
from chromosome abnormalities, 139–141
gonadectomy for, 115, 140
Gonadal function. See *Reproductive function.*
Gonadal steroids. See also *specific hormone.*
aging and, in men, 648–655
in women, 639–642
human immunodeficiency virus infection and, 750–755
Gonadectomy, for gonadal dysgenesis, 140
for 17α-hydroxylase deficiency, 115
Gonadotropin hormone-releasing hormone (GnRH), changes in aging men, 649
treatment effects on, 659–661, 663
changes in aging women, autopsy studies of, 633–634
hypothalamic, 614–617, 633–636
in pulse frequency, 634–635
in quantity secretion, 635–636
pituitary, 636–639
reproductive feedback response, 640–642
in hypothalamic amenorrhea, 614–617
in stress response, 713
puberty onset and, 530, 533
precocious, 539–540

Gonadotropin therapy, for ovulation, with congenital adrenal hyperplasia, 213, 221
Graves' disease, clinical symptom scales for, 416–419
thyroid autoantibodies in, clinical applications of assays for, 321–324
eye disease and, 324
immunobiology of, 316, 318–319
pregnancy management guidance with, 323–324, 326
radioiodine therapy guidance with, 322–323
remission prediction after thionamide therapy, 322
thyrotoxicosis causes and, 321–322
thyroid fine-needle aspiration biopsy for, 348, 364–365
thyroid scintigraphy of, 301, 304
thyroid ultrasonography of, 346–349
Group proteins, high mobility, as thyroid lesion marker, 388, 506
Growth and development, postnatal, with abnormal sex hormone production, 43–44, 50
with congenital adrenal hyperplasia, basal steroid imbalances and, 194
bone mineral density, 201–202
height outcomes, 124, 128, 197, 199–204
in adults, 124, 127
in children, 43–44, 121
penile length, 201
prenatal, 199–200, 202
therapeutic considerations of, **193–206**
weight changes, 200
Growth axis, stress response in, 715–716
Growth factors, intersex abnormalities and, 142–143
Growth hormone (GH). See also *Puberty; specific hormone.*
congenital adrenal hyperplasia and, 121, 128–129, 183
constitutional delay of, in puberty, 536–538
declining in aging men, 655–663
clinical consequences of, 658–659
neuroendocrine regulation in, 655–657
overview of, 647–648, 655–657, 664–665
physiologic changes in, 657–658
supplementation for, 659–661
androgen combined with, 663–664
exercise and, 662–663
long-term risks of, 662
side effects of, 661–662
excess secretion of. See *Acromegaly.*
gender differences and, in youth, 534–536
gonadotropin hormone-releasing hormone analogue-treated precocious puberty and, 539–540
human. See *Human growth hormone.*
human immunodeficiency virus infection and, 759–761
hyperglycemia associated with, 824, 826
physiologic changes with aging, 657–658
sex steroids, and puberty, **529–544**
androgens, 530–532
disorders of, 536–540
estrogens, 532–533
gender of youth and, 534–536
leptin, 534
timing of onset, 529–530
Growth hormone-binding protein (GHBP), puberty onset and, 534
Growth hormone deficiency (GHD), in adults, **545–563**
body composition and, 549, 553
bone density and, 549, 554–555
carbohydrate metabolism and, 553–554
cardiovascular system and, 547–548, 553
clinical presentation of, 546–549
etiology of, 545–546
insulin-like growth factor 1 and, 551–552
lipid profiles and, 547, 553
mortality of, 549–550
musculoskeletal system and, 548–549, 554
quality of life with, 549, 555
retesting with childhood onset, 552
testing for, 550–552
thyroid and, 554
treatment of, 553–556
contraindications to, 556
results of, 553–555
side effects of, 555–556
in children, causes of, 546
retesting adults for, 552
treatment side effects of, 556
in puberty, 536
Growth hormone receptor antagonists, for hypersomatotropism, 576
Growth hormone-releasing hormone (GHRH), excess, hypersomatotropism from, 566, 571
for growth hormone deficiency diagnosis, 550–551
for human immunodeficiency virus infection, 760–761
in aging men, 655–656, 658
Growth hormone secretagogue receptor (GHS-R), in aging men, 655–656
in energy balance regulation, 766, 768
Growth hormone therapy, for congenital adrenal hyperplasia, 204

Growth hormone therapy *(Continued)*
in aging men, 659–661
androgen combined with, 663–664
exercise and, 662–663
long-term risks of, 662
side effects of, 661–662
Gsα gene, as follicular thyroid cancer marker, 506

Handedness, androgen effects on, 185
learning disabilities and, 176
Hashimoto's thyroiditis, scintigraphy of, 299–300, 304–305, 312
thyroid autoantibodies in, 315–316, 319–320
ultrasonography of, 345–346
HbA_{1c}. See *Glycosylated hemoglobin.*
Heart failure, in diabetes mellitus, **1031–1046**
angiotensin-converting enzyme inhibitors for, 1039
beta-adrenergic antagonists for, 1039–1040
blood pressue control for, 1038–1039
cardiomyopathy versus, 1032
glycemic control for, 1040–1041
impact of, 1031–1033
insulin resistance in, 1037–1038
ischemic, 1033–1035
management of, 1038–1041
nonischemic, 1035–1038
oral hypoglycemic agents and, 1040–1041
risk factor modification for, 1038–1039
Heart Outcomes Prevention Evaluation (HOPE), 850–851, 1039
Heart rate variability, with coronary heart disease, diabetes mellitus and, 867
Heat tolerance, as hyperthyroid symptom, 417
Height, adult, with congenital adrenal hyperplasia treatment, 197, 199–200
improvement strategies, 203–204
short stature mechanisms, 124, 128, 199, 202–203
Hemagglutination assay, for thyroglobulin, 431–432
Hemodialysis, for end-stage renal disease, 840
Hemoglobin, in glycemic control. See *Glycosylated hemoglobin.*
Heparin, free thyroid hormone effects of, 280–281
during critical illness, 282, 284
in premature infants, 283
Heparin therapy, for hyperglycemic hyperosmolar syndrome, 822–823
Hepatic glucose production (HGP), in type 2 diabetes, 938
Hepatotoxicity, of oral antihyperglycemic agents, 926
Hermaphroditism, with congenital adrenal hyperplasia, 3, 94
as gender identity, 156
from chromosome abnormalities, 139–141
infant evaluation for, 220
with androgen deficiency, 141–142, 210
with androgen overexpression, 142–143
Heterozygotes, in nonclassical 21-hydroxylase deficiency, 42, 51–52
Hexarelin test, for growth hormone deficiency, 551
High mobility group proteins (HMGI), as thyroid lesion marker, 388, 506
High-performance liquid chromatography (HPLC), for urine free cortisol measurement, 731–733
Hirschsprung's disease, in multiple endocrine neoplasia type 2, genetic basis of, 495
Hirsutism, with congenital adrenal hyperplasia, 124
from 3β-hydroxysteroid dehydrogenase deficiency, 83, 92, 94
HLA gene, in 21-hydroxylase deficiency, 5–6, 37
HMG-CoA reductase agents, for dyslipidemia, 872, 1005–1007
HOE–901 insulin, for type 2 diabetes, 975
Home glucose monitoring (HGM), in type 2 diabetes, 942, 944–946
Hook effect, in thyroglobulin measurement, 436–437
Hormonal defects, of congenital adrenal hyperplasia, 31–32
owing to 21-hydroxylase deficiency, classical form, 46–48
nonclassical form, 50–51
Hormone(s). See also *specific hormone.*
bone mineral density and, 620
changes with age. See *Aging.*
Hormone replacement therapy. See also *specific hormone or medication.*
fibrinolytic activity and, 1021
for congenital adrenal hyperplasia, due to 21-hydroxylase deficiency, glucocorticoids. See *Glucocorticoid replacement therapy.*
mineralocorticoids. See *Mineralocorticoid replacement therapy.*
stress dosing of, 53–54, 143–144, 220
unresolved problems with, 122–124
sex hormones in, 95–96, 114–115, 199
in men, for aging, 648, 652–655

in women, for aging, 648
for hypothalamic amenorrhea, 622–623
Hst gene, in prolactinomas, 590
Human chorionic gonadotrophin (hCG), free thyroid hormone impact of, 276
Human growth hormone, for growth hormone deficiency, contraindications to, 556
dosage guidelines for, 556
side effects of, 555–556
therapeutic effects of, 553–555
Human immunodeficiency virus (HIV) infection, neuroendocrine abnormalities associated with, **749–764**
hypothalamic-pituitary-adrenal gland, 757–759
hypothalamic-pituitary-gonadal axis, 750–755
hypothalamic-pituitary-thyroid axis, 755–757
miscellaneous, 761
somatotropic axis, 759–761
Human insulin preparations, 943–944
analogue preparations versus, 974–976
Hürthle cells, in thyroid biopsy specimens, 370–371, 382–383, 390
tumors of, 438
Hydrocortisone, for adrenal crisis, 49
for congenital adrenal hyperplasia, 127
perioperative management of, 143–144
with 11β-hydroxylase deficiency, 68
with 17α-hydroxylase deficiency, 114
with pregnancy, 216–218, 220
alternative formulations or dose schedules, 129–130
due to 21-hydroxylase deficiency, 52–53, 216
growth and development effects of, 199, 202
reduced doses of, 126
stress dosing of, 53–54
unresolved problems with, 122
Hydrocortisone sodium succinate (Solu-Cortef), for congenital adrenal hyperplasia, 54
18-Hydroxycorticosterone, in 17α-hydroxylase deficiency, 104, 107
18-Hydroxycorticosterone deficiency, in aldosterone synthase deficiency, 70–71
in glucocorticoid-suppressible hyperaldosteronism, 72–74
11α-Hydroxylase deficiency, 101–116
17,20-lyase deficiency combined with, 101–105
molecular genetics of, 111–112
P450c17 deficiency in, diagnosis of, 105–109
management of, 113–116
molecular genetics of, 109–113
pathophysiology of, 101–104
pregnancy outcomes with, 221
11β-Hydroxylase, genetics of, 64–66
in biochemistry of adrenal steroids, 62–64
11β-Hydroxylase deficiency, in congenital adrenal hyperplasia, **61–79**
aldosterone synthase deficiency with, 69–72
clinical presentation of, 66–67
deoxycorticosterone levels with, 4–5, 66
glucocorticoid-suppressible hyperaldosteronism with, 72–76
molecular genetics of, 5–6, 68–69, 101
pathophysiology of, 1–2, 32–33
pregnancy outcomes with, 10, 69, 221
treatment of, 68–69
prenatal, 10, 69
11β-Hydroxylase isozymes, genetics of, 64–66
in biosynthesis of adrenal steroids, 62–64
17-Hydroxylase. See *P450c17*.
17α-Hydroxylase deficiency, in congenital adrenal hyperplasia, deoxycorticosterone levels in, 103–105, 107, 113–115
gonadal function with, 104–105, 114–115
hypertension with, 104–105, 114–115
pathophysiology of, 32–33
21-Hydroxylase deficiency, congenital adrenal hyperplasia owing to, **31–59**
basal steroid imbalances with, 194
biochemical consequences of, 33–35
classical, 3, 43–49
epidemiology of, 49
hormonal profile of, 46–48
other problems with, 45–46
physical stigmata in newborns with, 40, 42–43
postnatal abnormal sex hormone production with, 43–44, 50
pregnancy outcomes with, 208–220
reproductive function in men with, 45
reproductive function in women with, 44–45
salt-wasting with, 37, 40, 42, 48–51, 70
simple virilizing form of, 40–45
cognitive function with, 10–11, 46, **173–192**. See also *Cognitive function*.
diagnosis of, ACTH stimulation test for, 4
at birth, 3–4
prenatal, 4, 6
frequency of, 3
gene therapy for, 131–132

21-Hydroxylase deficiency *(Continued)*
growth and development considerations with, **193–206**
hormone replacement therapy for, 52–54
adult height and, 197–200, 202–204
bone mineral density and, 201–202
glucocorticoids, 52–53, 195–196
growth effects of, **193–206,** 200
mineralocorticoids, 54, 196–197
modalities for, 194–197
monitoring growth with, 197, 199–200
penile length, 201
prenatal, effects on growth, 199–200, 202
stress dosing, 53–54, 220
unresolved problems with, 122–124
weight changes and, 200–201
17-hydroxyprogesterone and, 32–33, 50–52
molecular genetics of, applied, 5–6, 8, 43
defect analysis in, 5, 35–40
genotype/phenotype correlation in, 5, 40–42
newborn screening for, 19–20
non-salt-wasting form of, genetics of, 37
nonclassical, 3, 49–52
clinical findings of, 49–50
heterozygotes with, 42, 51–52
hormonal profile of, 50–51
prevalence of, 51–52
pathophysiology of, 1–3, 31–33
pregnancy and, female fetus and maternal hyperandrogenism, 209–212
infant evaluation, 213, 220
labor and delivery, 220
lower fertility rates with, 208–209
outcomes with, 45, 50, 212–215
preconception issues, 213, 216, 221
treatment recommendations with, 8, 10–11, 213, 216–220
salt-wasting form of, 48–51, 70
genetics of, 37, 40, 42
simple virilizing form of, genetics of, 40–42
manifestations of, 43–45
17-Hydroxyprogesterone, in congenital adrenal hyperplasia, characteristic levels of, 20, 46–48
diagnosis of, 4, 6
due to 21-hydroxylase deficiency, 32–33, 50–52
glucocorticoid replacement therapy for, 53
growth and development effects of, 194, 197, 199, 201, 204
newborn screening for, 17, 19–21, 23, 46
pathophysiology of, 2–3
3β-Hydroxysteroid dehydrogenase (3β-HSD), functions of, 81–82
gene and protein encoding of, 84–87
genetic expression of, 82–83
3β-Hydroxysteroid dehydrogenase isozymes, encoding of, 84–87
3β-Hydroxysteroid dehydrogenase deficiency, in congenital adrenal hyperplasia, **81–99**
clinical spectra of, 83–84
gonadal function with, 94–95
hormonal types of, 84, 91–94
medical management of, 95–96
molecular genetics of, 87–91
pathophysiology of, 32–33, 83
protein encoding and, 84–87
Hyperactivity, as hyperthyroid symptom, 417
Hyperaldosteronism, glucocorticoid-suppressible, clinical presentation of, 72–74
genetic analysis of, 74–76
hyperglycemia associated with, 825
Hyperandrogenism. See *Androgen excess.*
Hypercortisolism. See *Cushing's syndrome.*
Hyperdynamic precordium, as hyperthyroid symptom, 418
Hyperestrogenism. See *Estrogen excess.*
Hyperfiltration, diabetic nephropathy and, 839
Hyperglycemia, diabetic. See *Diabetes mellitus; Diabetic hyperglycemia.*
drugs associated with, 825–827
endocrinopathies associated with, 819–820, 824–825
fasting, management of, 911, 956, 958
impaired endothelium-derived vasodilation in, 986–987
Hyperglycemic crises, in type 2 diabetes, **817–831**
diabetic ketoacidosis, 823–824
endocrinopathies, 824–825
hyperglycemic hyperosmolar syndrome, 817–823
medications resulting in, 825–827
Hyperglycemic hyperosmolar syndrome (HHS), in type 2 diabetes, 817–823
clinical findings with, 818, 821
epidemiology of, 817–818
illnesses associated with, 819–821
laboratory findings with, 818
precipitating factors of, 818–819
prevention of, 823
treatment of, 821–823
Hyperinsulinemic glucose clamping, 1037
Hypernatremia, adipsic. See *Adipsic hypernatremia.*

Hyperparathyroidism, genetic basis of, 499–500
hyperglycemia associated with, 825
Hyperprolactinemia, diagnosis of, 591–592
etiology of, 587–590
hyperglycemia associated with, 824
idiopathic, 588, 590
pathogenesis of, 590–591
treatment of, 592–600
bromocriptine for, 593–594, 601–604
medications for, 593–600
observation, 592
pregnancy and, 594, 601–604
radiotherapy, 593
surgical, 592–593
Hypersomatotropism. See *Acromegaly.*
Hypertension, in diabetes mellitus, **983–997**
arterial compliance and, 990–991
control studies on, 847–852, 869–870
coronary heart disease and, 869–870
endothelial dysfunction and, pathophysiology of, 985–990
treatment effects of, 991
epidemiology of, 983–984
hyperglycemia associated with, 819, 826, 839
microvascular complications associated with, 839
pathophysiology of, 984–985
with congenital adrenal hyperplasia, due to 11β-hydroxylase deficiency, 66–69
due to 17α-hydroxylase/17,20-lyase deficiencies, 104–105, 114–115
with glucocorticoid-suppressible hyperaldosteronism, 76
Hypertension in Diabetes Study (HDS), 847–848, 851
Hypertension Optimal Treatment (HOT) Study, 851–852, 870, 1023
Hyperthyroidism, clinical symptom scales for, 416–419
fetal, ultrasonography of, 345
with Graves' disease, 323
Graves' type. See *Graves' disease.*
hyperglycemia associated with, 824–825
metabolic indices of, 423–425
muscle function and, 422
neonatal, with Graves' disease, 323
organ-specific measures of, 420–422
serum proteins and enzymes in, 423
subclinical. See *Subclinical hyperthyroidism.*
thyroid scintigraphy of, 298–299, 304–306
treatment assessment, thyroid-stimulating hormone limitations in, 254
Hypertonic saline, for syndrome of inappropriate antidiuretic hormone, 692
Hypoglycemia, with congenital adrenal hyperplasia, cognitive function and, 177, 185
with insulin therapy, 941
Hypoglycemic agents. See *Insulin therapy; Oral antihyperglycemic agents.*
Hypogonadism, in aging men, 649, 659
stress response and, 714–715
with human immunodeficiency virus infection, 750–752
treatment effects on, 752–755
Hyponatremia, with congenital adrenal hyperplasia. See *Salt-wasting.*
dehydration and shock from. See *Adrenal crisis.*
with syndrome of inappropriate antidiuretic hormone, 687–690
differential diagnosis of, 690–691
treatment of, 691–692
Hypothalamic amenorrhea, **611–629**
adrenocorticotropin hormone in, 619
allopregnanolone in, 619
athletic, 612
beta-endorphin in, 619
corticotropin-releasing hormone in, 616, 619
cortisol in, 618
definition of, 612
dehydroepiandrosterone in, 618
eating disorder, 613, 615–618
etiology of, 614–617
idiopathic/functional, 613–614
insulin-like growth factor 1 in, 618
leptin in, 617–618
metabolic alterations with, 615–617
osteoporosis and, 619–622
overview of, 611–612, 623
physiologic basis for, 614–615
treatment of, 622–623
types of, 612–614
Hypothalamic obesity, in humans, 775
treatment of, 777–778
Hypothalamic-pituitary-adrenal (HPA) axis, Cushing's syndrome and, 730–731
during stress response, 696–699, 709–710
neuroendocrinology of, 697, 701–708
of growth and metabolism, 715–716
of reproductive axis, 713–715
with chronic hypoactivation, 720–721
human immunodeficiency virus infection and, 757–759
Hypothalamic-pituitary-gonadal axis, human immunodeficiency virus infection and, 750–755
Hypothalamic-pituitary-thyroid axis, human immunodeficiency virus infection and, 755–757
Hypothalamus, central processing unit of, in energy balance regulation, 767, 770–775

Hypothalamus *(Continued)*
functional changes of, in aging women, 632–636
autopsy studies of, 633–634
gonadotropin-releasing hormone pulse frequency, 634–635
gonadotropin-releasing hormone secretion quantity, 635–636
gonadotropin-releasing hormone studies, 633–634
in animal models, 632–633
in menopausal women, 633–636
prolactin secretion role of, 585–587
alterations in, 588–589
ventromedial, in energy balance regulation, 766–770
Hypothyroidism, central, testing for, thyroid-stimulating hormone limitations in, 252–254
clinical symptom scales for, 419–420
congenital, scintigraphy verification of, 304
thyroglobulin measurements in, 454–455
during pregnancy, 276–278
fetal, ultrasonography of, 345
free thyroid hormone levels with, 278
learning disabilities and, 178
metabolic indices of, 423–425
muscle function and, 422–423
myocyte enzymes in, 422–423
organ-specific measures of, 420–422
primary, autoantibody assays in, 329
serum proteins and enzymes in, 423
subclinical. See *Subclinical hypothyroidism.*
thyroid autoantibodies in, 327–329

Idiopathic hyperprolactinemia, 588, 590
Idiopathic hypothalamic amenorrhea, 613–614
Illness(es), critical, free thyroid hormone levels during, 281–283
diabetic ketoacidosis from, 823
hyperglycemic hyperosmolar syndrome from, 818–820
Immune dysfunction, learning disabilities and, 176
Immunochemiluminescence assay (ICMA), for thyroglobulin, 431–432, 434–436
Immunoextraction, in free thyroid hormone measurement, 269
Immunoradiometric assays (IRMA), for free thyroid hormone, 267, 269
commercial free T_4 methods, 271–273
for growth hormone disorders, 536, 551
for hypersomatotropism, 571
for metastases of thyroid cancer, 366
for thyroglobulin, 431–432, 434–437
Immunostaining. See *Tissue staining.*
Immunosuppression, with stress response, 696, 701, 709–710
in chronic hypoactivation, 720–721
Immunosuppressive drugs, hyperglycemia associated with, 819, 825–826
Implantable insulin pumps, external, 968–970
intraperitoneal, 970–973
Inborn errors of metabolism, newborn screening for, 16, 20, 46
Incidental lesions, thyroid, fine-needle aspiration biopsy of, 364–365
ultrasonography of, 354
Indium 111 octreotide scintigraphy, of metastatic thyroid cancer, 475, 482–483
Indium 111 pentreotide scintigraphy, of metastatic thyroid cancer, 475, 482–483
Infants. See *Newborns.*
Infections, hyperglycemic hyperosmolar syndrome from, 818–820
Infectious thyroiditis, acute, ultrasonography of, 347
Inferior petrosal sinus sampling (IPSS), for Cushing's syndrome, 740–743
Infertility, thyroid autoantibodies in, 326
Inflammatory bowel disease, delayed-release glucocorticoids for, 129–130
Inflammatory disease(s), stress response with, 711, 713–714, 721
Inhaled corticosteroids, Cushing's syndrome from, 737–738
Inhaled insulin, 942, 974
Injectable peptides, with insulin therapy, for type 2 diabetes, 976–977
Insulin, in energy balance regulation, 766–768, 777–778
Insulin algorithm forms, for home monitoring, 945–946
Insulin-like growth factor 1 (IGF–1), human immunodeficiency virus infection and, 759–760
hypothalamic amenorrhea and, 618
in growth hormone deficiency, 551–552
supplementation with, 659, 661–663
in hypersomatotropism, diagnostic levels, 571
excess production of, 566, 568–569
treatment goals for, 572, 576, 578
neuroendocrine regulation of, 657
puberty onset and, 532, 534–535
disorders of, 537
Insulin preparations, for type 2 diabetes, human versus analogues, 943–944, 974–976
Insulin pump therapy, external, 968–970
intraperitoneal, 970–973
Insulin resistance. See also *Diabetes mellitus type 2.*

aging and, 804
causes of, 804–808
clinical significance of, 812
congenital adrenal hyperplasia and, 44
definition of, 801
exercise and, 805–806
heart failure and, 1037–1038
measurement of, 801–802
obesity and, 806–807, 883–884, 898
pathogenesis of, **801–815**
free fatty acid-induced defect in, 802, 805–812
in diabetes mellitus, 803–804
pregnancy and, 804–805
with stress response, 716
Insulin resistance syndrome, components of, 920–921
Cushing's syndrome versus, 729–731
endothelial dysfunction and, 989, 1014
fibrinolytic system in, 1014
in diabetic dyslipidemia, 1000–1001, 1008
oral antihyperglycemic agents for, 919–921
general treatment considerations, 910–911
stress response versus, 716, 719
Insulin secretogogues, for diabetic hyperglycemia, cardiovascular risk factors and, 922
in combined therapy, 928–929
insulin resistance syndrome and, 921
mechanisms of actions, 912–914
side effects of, 923–925
Insulin sensitivity, in type 2 diabetes, exercise and, 892–893
molecular basis of, 893–894
hyperglycemia influence on, 823–825, 827
oral agents for. See *Oral antihyperglycemic agents.*
insulin therapy improvement of, 938–939
Insulin sensitizers, for diabetic hyperglycemia, dyslipidemia effects of, 1004, 1008
in combined therapy, 928–929, 965
insulin resistance syndrome and, 921
mechanisms of actions, 912, 914–916
Insulin therapy, for type 2 diabetes, **935–982**
algorithm forms for, 945–946
benefits of, 938–940
combination therapies, addition of oral agents, 961–968
addition to oral agents, 929, 945–955
practical strategies for, 927–929, 953–955
multiple-injection regimens, 955–960
practical strategies for, 961
sulfonylureas with, 928, 945–952, 961
delivery methods for, 968–974
external pump, 968–970
inhaled, 972, 974
intraperitoneal pump, 970–973
disadvantages of, 941–942
exercise and, 900
fibrinolytic activity and, 1020
for hyperglycemic hyperosmolar syndrome, 822
goals of, 942–943
home glucose monitoring of, 942, 944–946
in Diabetes Control and Complications Trial, 841–842, 868–869, 941
indications for, 943
injectable peptides and, 976–977
intrinsic coagulation system and, 1015–1016, 961–968
multiple-injection regimens for, 955–960
dose adjustment, 961
dose calculation, 961
preparations available, 943–944
analogues, 944, 974–976
rationale for, 936–938
summary of, 935–936, 977–978
with acarbose, 967–968
with glitazones, 965–966
with metformin, 961–965
sulfonylureas plus, 951–952, 961
with sulfonylureas, bedtime NPH insulin, 947–948
benefits of, 945–946, 952–953
dose adjustment, 954–955
dose calculation, 953–954
evening 70/30 insulin, 948
evening NPH insulin, 947
Lispro insulin, 950–951
metformin plus, 951–952, 961
patient selection, 953
various regimes, 928, 949–950
with troglitazone, 962–964
Insulin tolerance test, for growth hormone deficiency, 550–551
Intelligence quotient (IQ). See also *Cognitive function.*
with congenital adrenal hyperplasia, 174–175
with hypothyroidism, 178
Intersex abnormalities, with congenital adrenal hyperplasia. See also *Genitalia virilization.*
androgen deficient syndromes, 141–142
androgen overexpression syndromes, 142–143
due to chromosome abnormalities, 138–141
surgical reconstruction of, 143–150

Intersex abnormalities *(Continued)*
gender assignment with, 158–163
Intracranial hypertension, benign, from human growth hormone, 556
Intramyocellular triglyceride (IMCL-TG), in insulin resistance, 810, 812
Intraperitoneal insulin pump, 970–973
Intrathoracic goiters, 402, 407, 410
Intravenous fluids. See *Fluid replacement; Saline infusions.*
Intrinsic coagulation system, in type 2 diabetes, 873, 1012–1013
therapy for, 1015–1016
Iodine 123 (^{123}I), for thyroid scintiscanning, choice of, 300–301
clinical utility of, 301–312
for metastatic cancer, 474–475
radioactive properties of, 292–293
uptake measurement of, 293–297
Iodine 125 (^{125}I)-labeled coated tube assays, for congenital adrenal hyperplasia, in newborns, 19
Iodine 131 (^{131}I), for metastatic thyroid cancer imaging, patient preparation for, 472–473
sensitivity and specificity of, 469–472, 488
stunning effect of, 473–474
for thyroid scintiscanning, choice of, 300–301
clinical utility of, 301–312
for metastatic cancer, 469–474, 488
radioactive properties of, 292–293
thyroglobulin level discordance with after hormone withdrawal, 444–447
uptake measurement of, 293–297
Iodine contrast enhancement, of computed tomography, for substernal goiters, 405–407
Iodine deficiency, thyroglobulin measurements in, 454
Iodothyronine-binding proteins, in free thyroid hormone measurement, 265
assays for, 269–270
Irritable bowel syndrome, with chronic stress response, 711, 717, 720
Ischemia, recognized versus unrecognized, with diabetes mellitus, 865
Islet-cell antibodies, in diabetes mellitus, 824, 937
Isotope imaging. See also *Radioiodine uptake; specific radiopharmaceutical.*
of metastatic thyroid carcinoma, **469–492**
algorithm for, 485, 487–488
computed tomography versus, 471, 480, 482, 484, 487–488
noniodine, 475–485
radioiodine, 469–475
of thyroid. See *Thyroid scintiscanning.*
Isovolumic contraction time (ICT), cardiac, as thyroid function index, 421
Isovolumic relaxation time (IVRT), cardiac, as thyroid function index, 421

Kallikrein, in glucocorticoid-suppressible hyperaldosteronism, 76
Karyotypes and karyotyping, for genital ambiguity with congenital adrenal hyperplasia, due to 17α-hydroxylase deficiency, 105, 107, 113–115
due to 21-hydroxylase deficiency, 4, 8
gender development with, 155–163
intersex abnormalities with, 139–141, 143
sexual orientation with, 163–164
Ketoconazole, for congenital adrenal hyperplasia, 127
Kumamoto Study, on type 2 diabetes, 844–845
insulin therapy in, 935, 957–958

Labor and delivery. See also *Pregnancy.*
with congenital adrenal hyperplasia, stress dosing of glucocorticoids for, 220
Laboratory(ies), for newborn screening, availability and response of, 15–16, 18
protocol variations of, 18–21, 28
quality standards for, 21, 47
reporting procedures of, 16, 18, 21, 28
sample transport mechanisms of, 15, 18, 23
Lactic acidosis, with oral antihyperglycemic agents, 926
Lanreotide, for hypersomatotropism, 575–576
Laser photocoagulation, panretinal, for diabetic retinopathy, 834–836, 842, 845
Lateral hypothalamus (LHA), in energy balance regulation, 766–767, 776
Lateralization, of brain function, sex differences in, 185
Learning disabilities, assessment models for, 177–178
with congenital adrenal hyperplasia, 175–178
Left ventricular ejection time (LEVT), as thyroid function index, 420–421
Leptin, body composition role of, 617–618
growth hormone and, in puberty, 534
hypothalamic amenorrhea and, 617–618
in energy balance regulation, 766–767, 769–770
in type 2 diabetes, 807

Levothyroxine therapy, for subclinical hypothyroidism, 257
in subclinical hyperthyroidism, 259–260
thyroglobulin measurement and, 439
thyroid hormone monitoring with, 247, 253–254
thyroid scintiscan interference by, 299–300
LHRH-dependent precocious puberty, 121, 128–130
Libido, genital surgery impact on, 164–166
testosterone decline and, 650–651, 653
Lifestyle modifications, in type 2 diabetes. See also *Diet; Exercise.*
for heart failure, 1038–1039
Liothyronine therapy, thyroid hormone monitoring with, 247
Lipid levels, abnormal. See *Dyslipidemia.*
androgen supplementation and, 655
growth hormone deficiency and, 547, 553
Lipid metabolism, as thyroid function index, 424
thyroid hormone therapy impact on, 257
Lipid therapy, for cardiovascular disease, ADA thresholds for, 1002–1003
NCEP guidelines for, 1002, 1008
pharmacologic agents for, 1005–1008
for coronary heart disease, diabetes mellitus and, 872–873
Lipoid hyperplasia, in congenital adrenal hyperplasia, 32
Lisinopril, for diabetic nephropathy, 849–850
Lispro insulin, for type 2 diabetes, 944, 975
with sulfonylureas, 950–951
Locus caeruleus-norepinephrine system, in stress response, 697, 704–707, 710
Long-acting thyroid stimulator (LATS), immunobiology of, 318–319
Luteinizing hormone (LH), changes with aging, hypothalamic, 632–635
in men, 649–650
pituitary, 636–639
reproductive feedback response, 639–641
human immunodeficiency virus infection and, 750
in hypothalamic amenorrhea, 614–617
puberty onset and, 530, 534
stress response of, 713–715
Luteinizing hormone-releasing hormone (LHRH), puberty onset and, 534
Luteinizing hormone-releasing hormone (LHRH) agonist, for congenital adrenal hyperplasia, 121, 128–129
17,20-Lyase deficiency, 11α-hydroxylase deficiency combined with, 104–105
molecular genetics of, 111–112
hypertension with, 104–105, 114–115
isolated, 105
mutations causing, 112–113
Lymphadenopathy, with substernal goiter, 407
Lymphocytic thyroiditis, chronic, fine-needle aspiration biopsy of, 365, 370
Lymphoma, of thyroid. See *Thyroid lymphoma.*

Macrovascular disease, with diabetes mellitus. See *Hypertension; Insulin resistance syndrome.*
Macular edema, with diabetic retinopathy, 834–835
Magnetic resonance (MR) imaging, for Cushing's syndrome diagnosis, 738, 742–743
for diabetes insipidus differentiation, 682–683
for hyperprolactinemia, 591–592, 602, 604
for hypersomatotropism, 571, 578
of substernal goiters, **401–414**
appearance of, 408–409
decision to use, 409
patient selection for, 409–413
Malignant thyroid nodules. See *Thyroid carcinoma.*
Masculinization. See *Genitalia virilization.*
May-Grunwald-Giemsa smear, for fine-needle aspiration biopsy, of thyroid gland, 368
McCune-Albright syndrome, hypersomatotropism with, 566
Mediastinal goiters, imaging of, 407, 410
presentation of, 402–405
Medication. See *Drug(s).*
Medullary thyroid carcinoma (MTC), cytologic diagnosis of, 372, 390, 392
familial non- (FNMTC), genetic markers of, 505
fine-needle aspiration biopsy of, 365
hereditary/familial, management of, 499–501
RET proto-oncogene mutations in, 493–498
classification of, 500
screening for, 498–499
false results with, 500–501
management of, 374–375
genetic information in, 499–501
markers of, calcitonin as, 366
genetic, 493–498, 500–501, 505
sporadic, genetic markers of, 501
Melanocortin receptors, in energy balance regulation, 772–773
Melanocyte-stimulating hormone (MSH), excess of, ACTH and, 143

Melanocyte-stimulating hormone (MSH) *(Continued)*
in energy balance regulation, 771–772
Memory, glucocorticoid excess effects on, 182–183, 186
Men, aging in, neuroendocrinology of, **647–669**
combined interventions for, 663–664
gonadal axis and, 648–655
overview of, 647–648, 664–665
somatotropic axis and, 655–663
Menarche, congenital adrenal hyperplasia impact on, 44–45, 50, 84, 124
3β-hydroxysteroid dehydrogenase deficiency and, 84, 91–95
Menopause, neuroendocrinology of, **631–646**
gonadal steroid feedback response, 639–642
hypothalamic function changes, 632–636
neuroendocrine changes, 632
ovarian changes, 632
overview of, 631–632, 642
pituitary function changes, 636–639
Menstrual cycle, absence of. See *Amenorrhea.*
environmental stress and. See *Hypothalamic amenorrhea.*
physiology during puberty, 614
Mesocortical system, in stress response, 706
Mesolimbic system, in stress response, 706
Met, as thyroid lesion marker, 387–388
Metabolic alterations, with growth hormone deficiency, 547–548
treatment effect on, 553–554
with hypersomatotropism, 569
with hypothalamic amenorrhea, 615–617
with stress response, 698–701, 709, 716, 719
Metabolic syndrome X. See *Insulin resistance syndrome.*
Metabolism, exercise and, in type 2 diabetes, 805–806, 886
Metformin, for diabetic hyperglycemia, dyslipidemia effects of, 922, 1004
fibrinolytic activity and, 1018–1019
glycemic control with type 2 diabetes, 918–920
in combination therapy, 928–929
with insulin, 961–965
with insulin and sulfonylureas, 951–952, 961
insulin resistance syndrome and, 921
mechanism of actions, 912, 915–916
side effects of, 923, 925–926
with insulin therapy, 965–966
Methylprednisolone (Solu-Medrol), for congenital adrenal hyperplasia, 54
with pregnancy, 216, 218
Microalbuminuria, in diabetes mellitus, coronary heart disease and, 869–870
Microcarcinomas, of thyroid, fine-needle aspiration biopsy of, 365
Microvascular complications, of diabetes mellitus, **833–856**
blood pressure control and, 847–852
cardiovascular disease as, 921–922, 939–940, 990–1003
coronary heart disease as, **857–881**. See also *Coronary heart disease.*
glycemic control and, 840–847
nephropathy as, 836–840
retinopathy as, 833–836, 900
risk factors and prevention of, 840–852, 867–874, 933–940, 983–984
Mineralocorticoid(s), deficiency of, electrolyte imbalance with, 68, 70–71
excess of, with 17α-hydroxylase/17,20-lyase deficiencies, 104–105, 113–114
synthesis of, 33–35
Mineralocorticoid antagonists, for 17α-hydroxylase deficiency, 115
Mineralocorticoid replacement therapy, for congenital adrenal hyperplasia, due to 21-hydroxylase deficiency, 54
gestational management of, 217–220
modalities for, 196–197
renin-angiotensin system and, 54, 71
MIS gene, in sex differentiation, 138–142
Miscarriage, thyroid autoantibodies in, 326
Molecular genetics. See *Genetics and genetic analysis.*
Molecular markers. See *Genetic markers.*
Mood, growth hormone decline and, 658, 660
supplementation effects on, 660–661
testosterone decline and, 650–651
supplementation effects on, 653
Morphometric studies, of suspicious thyroid lesions, 385–387
Mortality rate, diabetes and, from hyperglycemic hyperosmolar syndrome, 818
insulin therapy and, 939–940
with coronary heart disease, 860–863
in acromegaly, 569–570
treatment effects on, 571–572
in growth hormone deficiency, 549–550
Mouse immunoglobulin antibodies, for thyroid-stimulating hormone assays, 250
Müllerian-inhibiting substance (MIS), in fetal sex differentiation, 138–139, 158
with chromosome abnormalities, 140–141
Müllerian structures, in fetal sex differentiation, 139–142

Multiple endocrine neoplasia type 1 (MEN–1), hypersomatotropism with, 566
prolactinomas with, 590–591
Multiple endocrine neoplasia type 2 (MEN2), genetic basis of, 493–498
use in clinical management, 499–501
genetic screening for, 498–499
false results with, 500–501
type A versus type B, 495
Muscles and muscle performance, as thyroid function index, 422–423
growth hormone deficiency and, 548–549
treatment effect on, 554, 660
human immunodeficiency virus infection and, 760
testosterone decline and, 650–651
supplementation effects on, 652–653, 753–754
Myocardial infarction, incidence of fatal, 861
with diabetes mellitus, 864–865, 983, 999
heart failure with, 1033–1035
Myocyte enzymes, as thyroid function index, 423
Myoglobin, as thyroid function index, 423

Nateglinide, for diabetic hyperglycemia, glycemic control with type 2 diabetes, 918–919
mechanism of actions, 912, 914
National Cholesterol Education Program (NCEP), lipid therapy guidelines, 1002, 1008
Nausea, arginine vasopressin secretion and, 675
Negative feedback regulation, of thyroid hormones, 245–246, 248
Neonates. See *Newborns.*
Nephropathy. See *Diabetic nephropathy.*
Nervous system(s), during stress response, 696–700
neuroendocrinology of, 697, 701–708
in energy balance regulation, 776–777
Nervousness, as hyperthyroid symptom, 416
Neuroendocrinology, growth hormone dysfunction in, 538
of aging, in men, **647–669**
combined interventions for, 663–664
gonadal axis and, 648–655
overview of, 647–648, 664–665
somatotropic axis and, 655–663
in women, **631–646**
gonadal steroid feedback response, 639–642
hypothalamic function changes, 632–636
neuroendocrine changes, 632
ovarian changes, 632
overview of, 631–632, 642
pituitary function changes, 636–639
of human immunodeficiency virus infection, **749–764**
hypothalamic-pituitary-adrenal gland abnormalities, 757–759
hypothalamic-pituitary-gonadal axis abnormalities, 750–755
hypothalamic-pituitary-thyroid axis abnormalities, 755–757
other associated dysfunctions, 761
somatotropic axis abnormalities, 759–761
of hypothalamic amenorrhea, 615–619
of obesity, **765–785**
afferent system in, 766–770
central processing in, 770–776
efferent system in, 776–779
energy balance regulation in, 766–767, 780
of stress response, **695–727**
body systems in, 709–716
dysfunction of, 716–721
emotions in, 708–709
neuroendocrinology of, 700–708
physiology of, 695–700
Neuromuscular dysfunction, from human growth hormone, 555–556
with hypersomatotropism, 568–569
Neuropathy. See *Diabetic neuropathy.*
Neuropeptide Y (NPY), in energy balance regulation, 768, 772
in stress response, 697, 700, 706
chronic hyperactivation and, 719–720
suppression of, 707–708
Neuropsychiatric disorders, thyroid disease and, 252, 257
Neurotransmitters, in stress response, 697, 700–701
New York Hospital-Cornell Medical Center, congenital adrenal hyperplasia at, prenatal experience with, 8, 10
Newborn screening, American Academy of Pediatrics recommendations for, 19–20
cost-effectiveness of, 19
definition of, 15
for congenital adrenal hyperplasia, **15–30**
counseling with, 47, 52, 216, 222
data collection forms for, 23–27
diagnostic algorithm for, 23
false-positive results with, 18, 20, 28
follow-up protocol for, 21, 23
gender assignment applications of, 156, 160
genitalia virilization results, 16–20, 23, 27–28

Newborn screening *(Continued)*
hormonal profile for, 46–48
international trends in, 17–18
racial/ethnic prevalence of, 16–18, 28
reporting procedures for, 16, 18, 21, 28
salt-wasting results, 16–17, 20–21, 23, 27–28
system for, 21–27
testing methods for, 18–21
U.S. trends in, 15–18
for inborn errors of metabolism, 16, 20, 46
historical evolution of, 16
multiple tests for, 17, 28
quality assurance programs for, 21, 47
Newborns, congenital hypothyroidism of, scintigraphy verification of, 304
hyperthyroidism of, with Graves' disease, 323
premature, free thyroid hormone levels of, 282–283
with congenital adrenal hyperplasia, gender assignment of, 161
gender identity and, 158–161
parent counseling for, 160–163
techniques for, 144–150
screening for, **15–30**. See also *Newborn screening.*
Niacin, hyperglycemia associated with, 826
Nicotinamide adenine dinucleotide phosphate (NADPH), in adrenal steroid synthesis, 64
Nicotine withdrawal, stress response with, 721
Nicotinic acid, for dyslipidemia, with diabetes mellitus, 1006, 1008
Nitric oxide (NO), in type 2 diabetes, as vasoactive factor, 985
cardiomyopathy and, 1035
endothelial dysfunction and, 985–986
endothelium-derived, 985
vasodilation and, 986–987
Nitric oxide synthase (NOS), in type 2 diabetes, exercise and, 895–897
Nodules, of thyroid. See *Thyroid nodules.*
Non-exercise-associated thermogenesis (NEAT), energy balance and, 779
Nonesterified fatty acids (NEFA), in free thyroid hormone measurement, 265, 273–274, 284
during critical illness, 281–282, 284
heparin effect on, 280–281, 283
Noniodine isotope imaging. See also *specific radiopharmaceutical.*
for metastatic thyroid carcinoma, 475–485, 488
Nonisotopic assays, for free thyroid hormone measurement, 269–270
Nonthyroidal illness, pituitary-thyroid axis in, 254–255
thyroid-stimulating hormone testing limitations in, 255
Norepinephrine, in energy balance regulation, 770
in stress response, 696, 698, 700
locus caeruleus system, 697, 704–706, 710
neuroendocrinology of, 701–702, 704
Nottingham Health Profile Questionnaire, in growth hormone deficiency, 549, 555
NPH insulin, for type 2 diabetes, insulin analogues versus, 944, 975–976
with sulfonylureas, at bedtime, 947–948
in evening, 947
Nucleus tractus solitarius (NTS), in energy balance regulation, 767, 776
Nutrition, thermic effect of, 779
Nutritional deficiencies, hypothalamic amenorrhea with, etiology of, 613, 615–618
treatment of, 622–623
with chronic stress response, 719–720

Obesity, behavioral factors of, 765–766
hypothalamic, 775, 777–778
neuroendocrinology of, **765–785**
afferent system in, 766–770
central processing in, 770–776
efferent system in, 767, 776–779
energy balance regulation in, 766–767, 780
type 2 diabetes and, 806–807, 883–884, 898
Octreotide, for hypersomatotropism, 574
for hypothalamic obesity, 777–778
Ophthalmopathy, in diabetes mellitus, 834–835
thyroid-associated, autoantibody assays for management of, 324
Opioid peptides, in stress response, 701, 704, 707
Optimal-gender policy, for sex reassignment, with congenital adrenal hyperplasia, 155–156, 159
Oral antihyperglycemic agents, for diabetic hyperglycemia, **909–933**
cardiovascular risk factors and, 921–922
combination therapies, addition of insulin to, 929, 945–955
addition to insulin, 961–968
addition to oral, 927–929
practical strategies for, 927–929, 953–955
exercise and, 900
general treatment considerations, 910–911

in Diabetes Control and Complications Trial, 869
insulin resistance syndrome and, 919–921
mechanisms of actions, 911–916
side effects of, 923–927
for type 2 diabetes, fibrinolytic activity and, 1018–1021
glycemic control with, 916–919, 936
heart failure and, 1040–1041
platelet inhibition with, 1025
Oral contraceptives, congenital adrenal hyperplasia and, fetal cautions with, 127
for 3β-hydroxysteroid dehydrogenase deficiency, 95–96
with progesterone replacement, 208
for hypothalamic amenorrhea, 622
Osmolality. See *specific type.*
Osteoporosis, with hypothalamic amenorrhea, 619–623
Ovarian hyperstimulation, free thyroid hormone impact of, 277–278
Ovaries, in fetal sex differentiation, 139, 142–143
polycystic, with congenital adrenal hyperplasia, 94–95, 124, 127, 209, 221
Ovulation, changes with aging, 632
congenital adrenal hyperplasia impact on, 44–45, 50, 94, 208
preconception management of, 213, 216, 221
dopamine agonist effects on, 601, 603
hypothalamic amenorrhea and, 622
Oxidative stress, in type 2 diabetes, 984, 987–989
cardiomyopathy and, 1033, 1035
exercise and, 895–897
Oxygen consumption, resting, as thyroid function index, 425

p53 tumor suppressor gene, as anaplastic thyroid cancer marker, 504, 506
P450 enzymes
in adrenal steroid synthesis, 63–64
P450c17 enzyme, in adrenal steroid synthesis, 63–64
genetic encoding alterations of, 101–104
P450c17 enzyme deficiencies, **101–119**
CYP17 gene and, 101–104
diagnosis of, 105, 107, 109
gonadal function with, 104–105, 114–115
molecular genetics of, 109, 111–113
amino acid substitutions, 111–112
deletions, premature truncations, frameshifts, and splicing errors, 109, 111
with isolated 17,20-lyase deficiency, 112–113
pathophysiology of, 104–105
with 17α-hydroxylase/17,20-lyase deficiency, 104–105
with isolated 17,20-lyase deficiency, 104–105, 112–113
P450c21 enzyme deficiency. See *21-Hydroxylase deficiency.*
Panhypopituitarism, with human immunodeficiency virus infection, 761
Papanicolau smear, for fine-needle aspiration biopsy, of thyroid gland, 368
Papillary thyroid carcinoma (PTC), cytologic diagnosis of, 371–372, 390
fine-needle aspiration biopsy for, 365
follicular variant of, 382–383, 388
genetic markers of, 502–503, 505–506
imaging of, 407, 409
incidence of, 502
management of, 374–375
RET proto-oncogene mutations in, 502–503
as diagnostic or prognostic tool, 505–506
thyroglobulin measurement with, 438, 443
Parasympathetic nervous system, in energy balance regulation, 777
Paraventricular nucleus (PVN), in energy balance regulation, 766–767, 772, 776
in stress response, 698–699
neuroendocrinology of, 701, 703–707
Patient compliance, with insulin therapy, 942
home monitoring and, 942, 944–946
Penis, congenital adrenal hyperplasia and, gender identity and, 159
length of, 201
surgical reconstruction to clitoris, 144–146
in fetal sex differentiation, 139, 142–143
Peno-vaginal intercourse, with sex reassignment, 155, 159
Pentamidine, hyperglycemia associated with, 826
Peptic ulceration, with chronic stress response, 711, 717, 720
Percutaneous ethanol injection therapy (PEIT), for cystic thyroid nodules, 355–356
Percutaneous transluminal coronary angioplasty (PTCA), with diabetes mellitus, 866
Pergolide (Permax), for hyperprolactinemia, 598
Perineal reconstruction, for virilized women, 144–150
Peripheral nervous system, during stress response, 696–700

Peroxisome proliferator-activated receptors (PPAR), insulin sensitivity and, 916, 927
Pertechnetate uptake, technetium 99m, in thyroid scintiscanning, 293, 297
clinical utility of, 301–312
pH-Dependent methacrylic acid copolymer, for congenital adrenal hyperplasia, 129–130
Phenylketonuria (PKU), newborn screening for, 16–17, 20
Pheochromocytoma, hyperglycemia associated with, 825
in multiple endocrine neoplasia type 2, genetic basis of, 495, 499–500
Photocoagulation, laser, for diabetic retinopathy, 834–836, 842, 845
Photon-beam therapy, for hypersomatotropism, 573
Physical activity. See *Exercise.*
Physical conditioning, in type 2 diabetes, for prevention, 897–898
with microvascular complications, 900–901
without complications, 898–900
Physician-patient relationship, with gender assignment, 156, 161–162
Pioglitazone, for diabetic hyperglycemia, dyslipidemia effects of, 1004
in combination therapy, 928
side effects of, 923, 926
Pituitary-adrenal axis. See *Hypothalamic-pituitary-adrenal (HPA) axis.*
Pituitary corticotropin, in congenital adrenal hyperplasia, 122
Pituitary function, changes in aging women, 636–639
in follicle-stimulating hormone isoform composition, 638–639
in humans, 637–639
in luteinizing hormone isoform composition, 638–639
in responsiveness to gonadotropin-releasing hormone, 639
in rodents, 636–637
Pituitary gland, diabetes insipidus and, 677, 683
human immunodeficiency virus infection and, 750–759, 761
in hypothalamic amenorrhea, 614–616
magnetic resonance imaging of, for Cushing's syndrome, 743
prolactin secretion role of, alterations in, 588–589
Pituitary-gonadal axis, human immunodeficiency virus infection and, 750–755
Pituitary hormones, in thyroid hormone regulation. See *Thyroid-stimulating hormone (TSH).*
Pituitary-thyroid axis, human immunodeficiency virus infection and, 755–757
in nonthyroidal illness, 254–255
Pituitary tumors. See also *specific type.*
hypersomatotropism from, 565, 568. See also *Acromegaly.*
extrapituitary disease versus, 566, 571
with congenital adrenal hyperplasia, 46
Placental metabolism, with congenital adrenal hyperplasia, of androgens, 209–212, 222
of glucocorticoid replacements, 216–220
Plasma fibrinopeptide A (FPA), in intrinsic coagulation system, with type 2 diabetes, 1013, 1015
Plasma osmolality, arginine vasopressin secretion and, 672–675
with adipsic hypernatremia, 685–686
with diabetes insipidus, 681
with syndrome of inappropriate antidiuretic hormone, 689–690
Plasma renin activity. See *Renin-angiotensin system.*
Plasminogen activator inhibitor–1 (PAI–1), in type 2 diabetes, coronary heart disease and, 873
insulin therapy and, 1016–1017
oral antidiabetic agents and, 1018–1021
procoagulant state of, 1013–1014
weight loss and, 1018
Platelet function, in diabetes mellitus, cardiovascular risks with, 873, 984
inhibitors for, 1021–1025
procoagulant state of, 1014–1015
Pleural fluid measurement, for thyroglobulin levels, 450–451
Polycystic ovary syndrome (POCS), with congenital adrenal hyperplasia, 124, 127, 209, 221
from 3β-hydroxysteroid dehydrogenase deficiency, 94–95
with Cushing's syndrome, 730, 737
Polydipsia, with diabetes insipidus, 676, 678–680
Polymerase chain reaction (PCR), for fetal DNA analysis, of congenital adrenal hyperplasia, 8
Polymorphism, genetic, genetic disease versus, 51
Polyps, colon, with hypersomatotropism, 569
Polyuria, in diabetes insipidus, 676, 679–680
POMC gene, in Cushing's syndrome, 739
in energy balance regulation, 771–772
in stress response, 696–698, 705, 707
of reproductive axis, 713–715

Population genetics. See also *Racial/ethnic prevalence.*
of congenital adrenal hyperplasia, 1, 3–4, 6, 37
per adult screening, 51
per newborn screening, 16–18, 28
Positron emission tomography (PET), fluoro–18-deoxyglucose, of metastatic thyroid cancer, 471, 483–485, 488
Postnatal depression, thyroid autoantibodies in, 326–327
Postpartum thyroiditis, scintigraphy of, 297, 299, 305–306
thyroglobulin measurements in, 453
thyroid autoantibodies in, 326–327
Potassium, imbalance of, with adrenal steroid deficiencies, 68, 70
with glucocorticoid-suppressible hyperaldosteronism, 72–73
with 17α-hydroxylase deficiency, 115
in ATP channels, insulin sensitivity and, 827
oral antihyperglycemic agents and, 913, 924–925
replacement of, for hyperglycemic hyperosmolar syndrome, 822
Power Doppler ultrasonography, for thyroid, 342
Prader stages, of genital masculinization, 8, 10, 23, 41
gender assignment and, 156, 158–161
Pravastatin, with diabetes mellitus, for coronary heart disease, 872–873
for dyslipidemia, 872, 1005–1007
Prealbumin, thyroxine-binding. See *Transthyretin (TTR).*
Precocious puberty, gonadotropin hormone-releasing hormone analogue-treated, 539–540
with congenital adrenal hyperplasia, 67, 128
LHRH-dependent, 121, 128–130
Preconception counseling, with congenital adrenal hyperplasia, 47, 52, 216, 222
Preconception fertility management, with congenital adrenal hyperplasia, 213, 216, 221
Prednisolone, for congenital adrenal hyperplasia, due to 21-hydroxylase deficiency, 195
with pregnancy, 216–218
Prednisone, for congenital adrenal hyperplasia, alternative formulations or dose schedules, 129
due to 21-hydroxylase deficiency, 53, 195
with pregnancy, 216, 218
Preejection period (PEP), cardiac, as thyroid function index, 420–421
Pregnancy, as thyroid scintiscan contraindication, 294
dopamine agonist therapy and, 594, 601–604
fetal development effects, 601
management recommendations, 603–604
prolactinoma size effects, 601–603
euthyroidism during, 323, 326
free thyroid hormone levels during, 276–278
stress response during, 220, 714
subclinical hypothyroidism during, 257
thyroid autoantibody assays during, for Graves' disease management, 323–324
postpartum, 326–327
with miscarriage and infertility, 326
thyroxine-binding globulin impact of, 268
type 2 diabetes and, 804–805
Pregnancy outcomes, with congenital adrenal hyperplasia, **207–229**
due to 21-hydroxylase deficiency, 45, 50, 208–220
female fetus and maternal hyperandrogenism, 209–212
gestational management of, 216–219
glucocorticoid replacement and, 208, 212–215
preconception management of, 213, 216
recommendations for, 216–222
in salt-wasting form, 208–209, 212–215, 217
infant evaluation, 213, 220
labor and delivery, 220
lower fertility rates, 208–209, 221
preconception issues, 213, 216, 221
prenatal management of, 10–11, 213, 216–220
summary of, 212–215
weight gain from treatment, 200, 217
Pregnenolone, in steroidogenesis, 33–35
P450c17 enzyme and, 101–103
Premature infants, free thyroid hormone levels of, 282–283
17-hydroxyprogesterone levels in, 20
Prenatal treatment, of congenital adrenal hyperplasia, **1–13**
algorithm for, 6–8
controversy over, 11
diagnostic breakthrough in, 6
effect on growth and development, 199–200, 202
gender development and, 10–11, 156
glucocorticoid replacement as, 208, 212–215
preconception management of, 213, 216
recommendations for, 216–222
molecular genetics of, 5–6

Prenatal treatment *(Continued)*
New York Hospital-Cornell Medical Center experience with, 8, 10
steroidogenesis in, 1–3
with 11β-hydroxylase deficiency, 10, 69
with 21-hydroxylase deficiency, 1, 3–5, 43
Primary hypothyroidism, autoantibody assays in, 329
Pro-opiomelanocortin. See *POMC gene.*
Procoagulant state, in type 2 diabetes, **1011–1030**
evidence for, 1012–1015
exercise therapy for, 1017–1018
fibrinolytic system, 1013–1014
therapy for, 1016–1025
intrinsic coagulation system, 873, 1012–1013
therapy for, 1015–1016
oral antidiabetic agents for, 1018–1021
platelet function in, 873, 984, 1014–1015
platelet inhibitors for, 1021–1025
vascular thrombosis, 1011–1012
weight loss for, 1018
with coronary heart disease, 873
Progesterone, congenital adrenal hyperplasia and, fertility effects of, 208, 216
growth and development effects of, 194
21-hydroxylase deficiency and, 48
synthesis of, 33–35
Progesterone replacement therapy, for 17α-hydroxylase deficiency, 115
for 3β-hydroxysteroid dehydrogenase deficiency, 95–96
Prolactin inhibitory factors (PIF), disorders of, 585–587
Prolactin releasing factors (PRF), disorders of, 585–587
Prolactin secretion disorders, **585–610**
diagnosis of, 591–592
etiology of, 587–590
natural history of, 590–591
neuroendocrine factors in, 585–587
pathogenesis of, 590–591
treatment of, 592–600
bromocriptine for, 593–598, 601–604
medications for, 593–600
observation, 592
pregnancy and, 594, 601–604
radiotherapy, 593
surgical, 592–593
Prolactinomas, hyperprolactinemia from, 588–590
natural history of, 590–591
overview of, 566, 585
pathogenesis of, 590–591
treatment of, 592–604
Prostate disease, androgen supplementation and, 654, 754
Protease inhibitors, body fat redistribution with, 758–759
hyperglycemia associated with, 825–826
Protein binding, in free thyroid hormone measurement, 273–274
during pregnancy, 276–278
Protein C, in intrinsic coagulation system, with type 2 diabetes, 1012, 1015–1016
Protein dependence, in free thyroid hormone measurement, 273, 275
during pregnancy, 276–278
in premature infants, 282–283
Protein restriction, for diabetic nephropathy, 840
Proteins, serum, as thyroid function index, 423
Pseudo-Cushing's syndrome, differential diagnosis of, 716, 719, 733, 735, 737
Psychologic stress, body system manifestations of, 711, 716
chronic dysfunctional response to, 717–721
neuroendocrinology of, 708–709
Psychologic well-being, testosterone decline and, 650–651
supplementation effects on, 653
with growth hormone deficiency, 549
treatment effects on, 555, 660–661
Psychosocial dwarfism, 720
Psychotic reaction, to bromocriptine, 597
PTEN gene, as follicular thyroid cancer marker, 504–505
PTTG gene, in prolactinomas, 590
Puberty, constitutional delay of, 536–538
gender differences and, 534–535
gonadotropin hormone-releasing hormone analogue-treated precocious, 539–540
growth disorders during, 536–540
growth hormone deficiency in, 536
hormonal events at, 530–535
androgens, 530–532
estrogens, 532–533
leptin, 534
human immunodeficiency virus infection and, 760
menstrual cycle physiology with, 614
timing of onset, 529–530
Public health systems, newborn screening programs in, 15–18, 23
Pulmonary function tests, for substernal goiter, 413
Pulsatile secretion, of thyroid-stimulating hormone, 250
Pyogenic thyroiditis, ultrasonography of, 347

Quality of life, with gender assignment, 156, 161–163, 166–167
with growth hormone deficiency, 549
treatment effects on, 555
Quinagolide (CV 205–502), for hyperprolactinemia, 598

Racial/ethnic prevalence, of congenital adrenal hyperplasia, aldosterone synthase deficiency in, 70–71
genetic analysis of, 1, 3–4, 6, 37
11β-hydroxylase deficiency in, 61, 69, 221
21-hydroxylase deficiency in, 51
P450c17 enzyme deficiencies in, 112–113
with newborn screening, 16–18, 28, 222
Radiation, for hypersomatotropism, 573, 576–577
for prolactinomas, 593
Radiochemical purity, in free thyroid hormone measurement, 273
Radioimmunoassays (RIA), for free thyroid hormone, 269, 271–273
for growth hormone disorders, 551
for newborn screening, of congenital adrenal hyperplasia, 16, 19, 48, 217–219
for thyroglobulin, 429–432, 434–436
for thyroid-stimulating hormone, 249–250
Radioiodine ablation therapy, for malignant thyroid lesions, thyroglobulin measurement with, 441, 443–444
Radioiodine therapy, for thyroid disease, autoantibody assays for guiding, 322–323
magnetic resonance imaging with, 409
pregnancy impact of, 323
Radioiodine uptake, thyroid scintiscanning and, **291–313**. See also *Thyroid scintiscanning.*
Radionuclide(s). See *Radiopharmaceutical(s).*
Radiopharmaceutical(s). See also *specific agent.*
in imaging for metastatic thyroid cancer, algorithm for, 485, 487–488
noniodine, 475–485
radioiodine, 469–475
in thyroid scintiscanning, 292–293
choice of, 300–301
RAS gene, as thyroid cancer marker, follicular, 503–506
papillary, 503
Reactive oxygen species (ROS), in diabetes mellitus, 984, 986–989
Real-time technique, in thyroid ultrasonography, 341, 367
Recombinant thyrotropin (rhTSH), stimulation in thyroid carcinoma, for isotope imaging, 472–473, 485
thyroglobulin measurement and, 439–440
Renal biospy, in transplantation studies, for glycemic control, 846–847
Renal function, deterioration of, with diabetes mellitus, 836–840, 869–870
with heart failure, 1041
Renal transplantation, for end-stage renal disease, 840
renal biospies in, for glycemic control studies, 846–847
Renin-angiotensin system, in congenital adrenal hyperplasia, *CYP11B2* expression and, 66
gestational monitoring of, 217
mineralocorticoid therapy and, 54, 71
with 11β-hydroxylase deficiency, 66–68
in glucocorticoid-suppressible hyperaldosteronism, 72–73
Repaglinide, for diabetic hyperglycemia, glycemic control with type 2 diabetes, 918–919
mechanism of actions, 912, 914
Replacement therapy, for thyroid hormones. See *Thyroid hormone therapy.*
Reproductive axis, in gonadal steroids and aging, 639–642
effects in men, 651 , 653
feedback in women, 639–642
stress response in, 713–715
Reproductive dysfunction, exercise-induced. See *Hypothalamic amenorrhea.*
Reproductive function, with congenital adrenal hyperplasia. See also *Gonadal dysgenesis.*
gonadotropin therapy for, 213, 221
17α-hydroxylase deficiency and, 104–105, 114–115
3β-hydroxysteroid dehydrogenase deficiency and, 81, 83, 94–95
in men, 45, 50
in women, 44–45, 50
sex differentiation and, 138–141
Resection. See *Surgical resection.*
Respiratory dysfunction, with bromocriptine, 597
with hypersomatotropism, 568
Resting energy expenditure, in energy regulation, 778–779
RET proto-oncogene, as thyroid cancer marker, medullary, 493–495
mutation spectrums in, 495–497, 500
papillary, 502–503, 505–506
sporadic, 501

RET proto-oncogene *(Continued)*
in multiple endocrine neoplasia type 2, 493–501
mutations of, classification of, 500
spectrum of, 495–497
structure and function of, 494–495
tyrosine kinase activation by, 494, 497–498
Retinopathy, diabetic. See *Diabetic retinopathy.*
Revascularization, coronary, with diabetes mellitus, 866
Reverse transcription-polymerase chain reaction (RT-PCR), thyroid cancer applications of, for metastases identification, 366
for thyroglobulin mRNA levels, 448–449, 507
in fine-needle aspiration biopsy, 449
in peripheral blood, 449–450
for tumor surveillance, 506–507
rhGH. See *Growth hormone-releasing hormone (GHRH).*
mRNA, thyroglobulin, as thyroid cancer marker, 448–449
in fine-needle aspiration biopsy, 449
in peripheral blood, 449–450
Rodents, changes with aging in, of hypothalamic function, 632–633
of pituitary function, 636–637
Rosiglitazone, for diabetic hyperglycemia, dyslipidemia effects of, 1004
in combination therapy, 928
side effects of, 923, 926

Salicylates, thyroxine-binding globulin impact of, 280
Saline infusions, for hyperglycemic hyperosmolar syndrome, 821–822
hypertonic, for syndrome of inappropriate antidiuretic hormone, 692
isotonic, for adrenal crisis, 49
Salivary cortisol, late-night, in Cushing's syndrome, 734–736
Salt balance, antidiuretic hormone regulation of, 675–676
Salt-preservation, with congenital adrenal hyperplasia, 4, 31
Salt wasters, 48
Salt-wasting, with congenital adrenal hyperplasia, cognitive function and, 174–175, 185
due to 21-hydroxylase deficiency, 31, 37, 40, 42, 48–51, 70
due to 3β-hydroxysteroid dehydrogenase deficiency, 83–84, 87, 91
newborn screening for, 16–17, 20–21, 23, 27–28
treatment of, 54
Sandostatin LAR, for hypersomatotropism, 574–575, 577
Satiety signals, in energy balance regulation, afferent, 766, 768–769
central processing of, 767, 770–775
efferent, 776–779
Scintigraphy, of thyroid. See also *Thyroid scintiscanning.*
noniodine uptake and, 477–485
radioiodine uptake and, **291–313**
Screening guidelines, for diabetic nephropathy, 838–839
for diabetic retinopathy, 834–835
Screening tests, for adults. See *Adult screening.*
for newborns. See *Newborn screening.*
Seasonal variability, of thyroid-stimulating hormone, 250
Sedentary lifestype, type 2 diabetes and, 883–884
Seizures, with hyperglycemic hyperosmolar syndrome, 821
Self-reporting, of diabetes mellitus, 858–859
Serotonin (5-HT), in energy balance regulation, 771
Serum enzymes, as thyroid function index, 423
Serum osmolality, in hyperglycemic hyperosmolar syndrome, 818–819, 822
Serum proteins, as thyroid function index, 423
70/30 insulin, for type 2 diabetes, with sulfonylureas, 948
Sex behavior. See *Sexual activity.*
Sex differentiation. See *Genitalia differentiation.*
Sex hormone-binding globulin (SHBG), in placental activity, gestational monitoring of, 217–219
with maternal hyperandrogenism, 212
Sex hormone precursors, excess of, in congenital adrenal hyperplasia, 1–3, 31, 33
genotype/phenotype correlation of, 40–43
Sex hormones. See also *specific hormone.*
for congenital adrenal hyperplasia, 95–96, 114–115, 199
synthesis of, 33–35
abnormal, postnatal signs of, 43–44, 50
Sex steroids, growth hormone and, **529–544**
androgens, 530–532
disorders of, 536–540
estrogens, 532–533
gender differences in youth, 534–536
leptin, 534
puberty timing with, 529–530

stress response of, 713–715
Sexual activity, brain sex differences in, 184
with congenital adrenal hyperplasia, 164–166
gender surgery implications of, 156, 166–167
genital examinations and, 167
sexuality counseling for, 167
Sexual function, testosterone decline and, 650–651, 653
Sexual orientation, with congenital adrenal hyperplasia, 163, 208
clinical implications of, 163–164
Sexuality, in congenital adrenal hyperplasia, **155–171**
gender development with, 156–163
sexual activity with, 164–167
sexual orientation with, 163–164
Sexuality counseling, for intersex abnormalities, 167
SF–1 gene, in sex differentiation, 138–139
Sialic acid, in thyroglobulin biosynthesis, 430
Sick-day treatments, preventive, for hyperglycemic hyperosmolar syndrome, 823
Signal-transduction molecules, in type 2 diabetes, exercise and, 890–892
Silent ischemia, with coronary heart disease, in diabetes mellitus, 865, 1033
Silent thyroiditis, autoantibody assays in, 322
scintigraphy of, 297, 299, 305–306
Simple virilizers, 33
due to 21-hydroxylase deficiency, 40–45
Simvastatin, for dyslipidemia, with diabetes mellitus, 872, 1005–1007
Single-photon emission tomography (SPECT), of thyroid cancer, noniodine isotopes for, 475, 479–480, 482–483
Sinus sampling, inferior petrosal, for Cushing's syndrome, 740–743
Sipple's syndrome, genetic basis of, 495
Skeletal overgrowth, with hypersomatotropism, 568
Skin changes, with hypersomatotropism, 568
Sleep apnea, androgen supplementation and, 655
Sleep disorders, growth hormone decline and, 657–659
supplementation effects on, 660–661
thyroid disease and, 250, 252
Sodium, serum, in hyperglycemic hyperosmolar syndrome, 818–819, 822
Sodium chloride supplements, for congenital adrenal hyperplasia, due to aldosterone synthase deficiency, 71
due to 21-hydroxylase deficiency, 54
Sodium imbalance, adipsic. See *Adipsic hypernatremia.*
with congenital adrenal hyperplasia. See *Adrenal crisis; Salt-wasting.*
with syndrome of inappropriate antidiuretic hormone, 687–690
differential diagnosis of, 690–691
treatment of, 691–692
Sodium-iodide symporter (NIS) antibodies, clinical applications of, 321–329
immunobiology of, 315, 319–320
Sodium restriction, for 17α-hydroxylase deficiency, 114
Somatopause, neuroendocrinology of, 655–663
clinical consequences of, 658–659
growth hormone changes in, 657–658
growth hormone regulation in, 655–657
growth hormone treatment of, 659–661
androgen combined with, 663–664
exercise and, 662–663
side effects and risks of, 661–662
overview of, 647–648, 655–657, 664–665
Somatostatin(s), declining levels in aging men, 655, 658. See also *Somatopause.*
Somatostatin (SRIF) receptor ligands, for hypersomatotropism, 574–577
Somatostatin receptor scintigraphy, of metastatic thyroid cancer, 475, 482–483
Somatotropic axis, neuroendocrinology of, in aging men, 655–663
with human immunodeficiency virus infection, 759–761
SOX 9 gene, in sex differentiation, 138–139
Spatial abilities, with congenital adrenal hyperplasia, 178–181, 183
Sperm count, congenital adrenal hyperplasia impact on, 44–45, 50
Spironolactone, for congenital adrenal hyperplasia, 68, 125
Sports participation, amenorrhea and. See *Hypothalamic amenorrhea.*
SRY (sex-determining region of Y chromosome), congenital adrenal hyperplasia and, 138–139
Sry gene, in gonadal dysgenesis, 139, 141
Statin agents, for dyslipidemia, 872–873, 1005–1007
for hypersomatotropism, 574–575, 577
Statistical methods, for thyroid lesion diagnosis, integration of, 389, 394
Steroid esters, for congenital adrenal hyperplasia, 129–130
Steroid replacement therapy. See *Hormone replacement therapy; specific hormone.*
Steroidogenesis, enzymes of, drugs inhibiting, 127
in intersex abnormalities, 141–142

Steroidogenesis *(Continued)*
pathways of, 1–3, 33–35
11β-hydroxylase in, 62–64
21-hydroxylase deficiency in, 31–35
3β-hydroxysteroid dehydrogenase in, 81–82
P450c17 in, 101–102
with congenital adrenal hyperplasia, 4–5, 31–32
Stimulation tests, for growth hormone deficiency, 550–551
Stockholm Diabetes Intervention Study (SDIS), 844
Strength. See *Muscles and muscle performance.*
Stress, cortisol production with, 51
environmental, amenorrhea from. See *Hypothalamic amenorrhea.*
mechanical, bone mineral density and, 620
Stress dosing, of hormone therapy, for congenital adrenal hyperplasia, due to 21-hydroxylase deficiency, 53–54
during labor and delivery, 220
perioperative, 54, 143–144
Stress response, **695–727**
body systems in, 709–716
gastrointestinal, 711–713, 720
growth axis, 715–716
immune, 696, 701, 709–710, 720–721
metabolism, 698–701, 709, 716, 719
reproductive axis, 713–715
thyroid function, 707, 715, 720–721
Cushing's syndrome versus, 716, 719
during pregnancy, 714
dysfunction of, 716–721
chronic hyperactivation as, 717–720
chronic hypoactivation as, 720–721
emotions in, 708–709
fine tuning with, 716–717
neuroendocrinology of, 700–708
arginine vasopressin, 705
corticotropin-releasing hormone, 701–704
locus caeruleus-norepinephrine system, 704–705, 710
miscellaneous systems, 706–708
neuropeptide Y, 706
physiology of, 695–700
autonomic limb, 700
endocrine limb, 698–699
psychologic, 708–709
with inflammatory disease, 711, 713–714, 721
Stunning effect, of iodine 131, in metastatic thyroid cancer imaging, 473–474
Subacute thyroiditis, autoantibody assays in, 322, 327–328
scintigraphy of, 297, 299, 305–306
thyroglobulin measurements in, 451–452
ultrasonography of, 347–348
Subclinical hyperthyroidism, clinical significance of, 258
clinical symptom scale for, 419
computed tomography of, 406–407
definition of, 257
epidemiology and natural history of, 257
prevention of, 258–260
thyroid-stimulating hormone measurements in, 257–260
treatment of, 258–260
Subclinical hypothyroidism, autoantibody assays in, 327–329
definition of, 256
epidemiology and natural history of, 256
thyroid hormone treatment of, 256–257
thyroid-stimulating hormone measurements in, 256–257
Subclinical thyroid disease. See also *Subclinical hyperthyroidism; Subclinical hypothyroidism.*
thyroid-stimulating hormone measurements in, 256–260
Substance P, in stress response, 707
Substernal goiters, imaging of, **401–414**
computed tomography appearance, 405–408
magnetic resonance imaging appearance, 408–409
patient selection for, 409–413
technique to use, 409
presentation of, 401–405
Sulfonylureas, for diabetic hyperglycemia, cardiovascular risk factors and, 922
fibrinolytic activity and, 1019
heart failure and, 1040
mechanism of actions, 912
side effects of, 923–924
with insulin therapy, bedtime NPH insulin, 947–948
benefits of, 945–946, 952–953
dose adjustment, 954–955
dose calculation, 953–954
evening 70/30 insulin, 948
evening NPH insulin, 947
Lispro insulin, 950–951
metformin plus, 951–952, 961
patient selection, 953
various regimes, 928, 949–950
Superior vena cava syndrome, with goiters, 405
SUR 1 subunit, oral antihyperglycemic agents and, 913–914, 925
Surgery, hydrocortisone replacement therapy with, 54, 143–144
hyperglycemic hyperosmolar syndrome from, 819–821
Surgical resection, for hyperprolactinemia, 592–593

for hypersomatotropism, 572–573, 576–577
Suspicious lesions, of thyroid, 382–389
cytologic aspects of, 382–383
cytometric DNA measurements for, 384
molecular markers for, 387–389
morphometric studies of, 385–387
statistical integration of diagnostic data, 389, 394
subgrouping with increasing cytologic atypia, 383–384
Sweating, as hyperthyroid symptom, 417
Sympathetic nervous system, during stress response, 696–697, 700
neuroendocrinology of, 703, 710
in energy balance regulation, 776–777
Syndrome of inappropriate antidiuretic hormone (SIADH), 687–692
chronic, 692
clinical characteristics of, 687–688
definition of, 687–688
differential diagnosis of, 690
etiology of, 688
pathophysiology of, 688–690
treatment of, 691–692
Syndrome X. See *Insulin resistance syndrome.*
Systolic Hypertension in Europe (Syst-Eur) Trial, 851, 869

T_3 resin uptake, free thyroid hormone measurement by, 266, 270
estimation of free T_4 concentration for, 271–276
Technetium–99m (^{99m}Tc), for thyroid metastatic cancer imaging, 475, 480–485, 488
for thyroid scintiscanning, choice of, 300–301
radioactive properties of, 292–293
uptake measurement of, 293–297
Technetium–99m furifosmin, for metastatic thyroid cancer imaging, 475, 483, 488
Technetium–99m pertechnetate, for metastatic thyroid cancer imaging, 475, 482, 488
in thyroid scintiscanning, 293, 297
clinical utility of, 301–312
Technetium–99m sestamibi, for metastatic thyroid cancer imaging, 475, 480–481, 488
Technetium–99m tetrofosmin, for metastatic thyroid cancer imaging, 475, 481–482, 488
Telomerase, as thyroid lesion marker, 388
Temperature dependence, in free thyroid hormone measurement, 274
Teratogen(s), antiandrogens as, 127
bromocriptine as, 594, 601–604
Testes, in fetal sex differentiation, 139–142
Testicular adrenal rests, with congenital adrenal hyperplasia, 46, 50, 124
Testicular tumors, with congenital adrenal hyperplasia, 46, 50
Testolactone, for congenital adrenal hyperplasia, 125–126
adult height and, 199
Testosterone, developmental pattern of, 648–649
in brain differentiation, 158, 175–176
protective mechanisms in fetus, 209–212
in congenital adrenal hyperplasia, 33
for 17α-hydroxylase deficiency, 114–115
glucocorticoid replacement therapy and, 53
intersex abnormalities, 141–142
placental aromatization of, female fetus development and, 209–212
gestational management of, 217–219, 222
in fetal sex differentiation, 139, 141, 158, 209–212
in stress response, 715
synthesis of, 1–3, 33–35
Testosterone deficiency, in aging men, 648–649
clinical consequences of, 650–651
epidemiology of, 649
physiology of, 649–650
supplementation for, 652–655
growth hormone with, 663–664
with human immunodeficiency virus infection, 750–755
as adaptation versus maladaptation, 751
pathophysiology of, 750–751
poor disease outcome correlation of, 751–752
replacement for, 752–755
Testosterone replacement, 53
for 3β-hydroxysteroid dehydrogenase deficiency, 95
in aging men, clinical trials of, 652–653
growth hormone with, 663–664
side effects of, 654–655
with human immunodeficiency virus infection, adverse effects of, 754
effects of, 752–754
recommendations for, 755
Thallium 201 chloride, for metastatic thyroid cancer imaging, 475, 477–480, 488
Thermic effect, of food, in energy balance regulation, 779
Thermogenesis, in energy balance regulation, 779

Thiazide diuretics, hyperglycemia associated with, 819, 826
Thiazolidinediones, for diabetic hyperglycemia, cardiovascular risk factors and, 922
fibrinolytic activity and, 1019
heart failure and, 1040–1041
mechanism of actions, 912, 916
side effects of, 923, 926–927
Thionamide therapy, for hyperthyroidism, remission prediction with, 322
Thirst, antidiuretic hormone interaction with, 675–676
with adipsic hypernatremia, 685–687
Thromboembolism, with hyperglycemic hyperosmolar syndrome, 821–822
Thrombosis, vascular, in type 2 diabetes, 1011–1012
Thromboxane, inhibitors of, for procoagulant state, 1021
Thyroglobulin, autoimmunity to. See *Thyroglobulin antibodies (Anti-Tg).*
gene regulation and biosynthesis of, 430–431
serum measurement of, **429–467**
assays for, 429–430
overcoming limitations of, 436–437
triumphs and tribulations of, 434–436
cystic and pleural fluid in, 451
elevated causes of, 432–434
in clinical practice, 429, 437–455
in congenital hypothyroidism, 454–455
in differentiated thyroid cancer, 366, 437–448
in iodine deficiency, 454
in postpartum thyroiditis, 453
in solitary thyroid nodules, 453–454
in subacute thyroiditis, 451–452
in thyrotoxicosis factitia, 452–453
international standard for, 437
reverse transcription-polymerase chain reaction for mRNA in, 448–450
tissue staining and levels in, 450–451
Thyroglobulin antibodies (Anti-Tg), assay detection of, 320, 431–432
clinical applications of, 321–329, 432
immunobiology of, 315–316, 318, 431
in thyroid cancer, 329, 447
prognostic significance of, 447–448
reverse transcription-polymerase chain reaction and, 449–450
interference in thyroglobulin measurement, 434–436
testing indications for, 330
Thyroglobulin mRNA, as thyroid cancer marker, 448–449
in fine-needle aspiration biopsy, 449
in peripheral blood, 449–450
Thyroglossal duct cyst, as ectopic thyroid, 344
Thyroid adenomas, follicular, cytologic diagnosis of, 371, 375
genetic transition to carcinoma, 502–503
Thyroid autoantibodies, **315–337**
assay detection of, 315, 320–321
clinical applications of, 321–329
discovery of, 315, 331
immunobiology of, 316, 318–320
in depression, 329
in free thyroid hormone measurement, 268–269, 271–272
in goiter disease, 327–329
in Graves' disease, clinical applications of assays for, 321–324
eye disease and, 324
immunobiology of, 316, 318–319
pregnancy management guidance with, 323–324, 326
radioiodine therapy guidance with, 322–323
remission prediction after thionamide therapy, 322
thyrotoxicosis causes and, 321–322
in Hashimoto's thyroiditis, 315–316, 319–320
in hypothyroidism, 327–329
in thyroid cancer, 329
pregnancy applications of, management guidance with, 323–324, 326
miscarriage and infertility, 326
postpartum complications, 326–327
testing indications for, 330–331
Thyroid-binding globulin (TBG), human immunodeficiency virus infection and, 755
Thyroid carcinoma. See also *specific type.*
cytologic diagnosis of, 369–373
accuracy of, 372–373, 375
for management guidance, 373–389
differentiated, thyroglobulin measurement in, 366, 437–438
after recombinant thyrotropin stimulation, 439–440
cystic and pleural fluids for, 450–451
discordance with whole-body scan after hormone withdrawal, 444–447
predictive/prognostic value of, 441, 447–448
reevaluation indications with, 440–441
reverse transcription-polymerase chain reaction role in, 448–450
therapy indications with, 440–441
thyroglobulin antibodies and patient management with, 447
thyroglobulin antibodies prognostic significance with, 447–448

thyroid hormone impact on, 438–439
tissue staining for, 450–451
with previous thyroid ablation therapy, 441, 443–444
with thyroid remnants, 441, 443
fine-needle aspiration biopsy of, 364–366, 373
as followup, 381–382
goiter versus, computed tomography of, 407
imaging of. See also *specific technique.*
as followup, 354, 381
metastatic, **469–492**
techniques for, 352–354, 407, 409–410, 413, 446
thyroglobulin level discordance with after hormone withdrawal, 444–447
management of, 374–375
cytologic diagnosis in, 373–374
suspicious lesions, 382–389
thyroglobulin levels in, 440–441
markers of, 366, 437–438, 448
genetic, 493–507
metastatic, isotope imaging for, **469–492**
algorithm for, 485, 487–488
noniodine, 475–485
radioiodine, 469–475
thyroid-stimulating hormone stimulation in, 472–473, 485, 487–488
to cervical lymph nodes, 365–366, 449
reverse transcription-polymerase chain reaction role in, 366, 448–450, 506–507
suspicious lesions of, 382–389
cytologic aspects of, 382–383
cytometric DNA measurements for, 384
molecular markers for, 387–389
morphometric studies of, 385–387
statistical integration of diagnostic data, 389
subgrouping with increasing cytologic atypia, 383–384
thyroid autoantibodies in, 329, 447–450
thyroid-stimulating hormone suppression for, 253, 257, 260
scintigraphy of, 310, 312
Thyroid cysts, computed tomography of, 405
diagnostic problems of, 389–390
management of, 389–390
therapeutic injection of, 352, 355
ultrasonography of, 350–352
Thyroid disease, assessment of, with thyroid-stimulating hormone, 251–252
limitations of, 252–254
screening for, with thyroid-stimulating hormone, 251–252
limitations of, 252–254
subclinical. See also *Subclinical hyperthyroidism; Subclinical hypothyroidism.*
thyroid-stimulating hormone measurements in, 256–260
thyroglobulin antibodies in, 432
thyroid-stimulating hormone-free thyroxine relationship deviations in, 284–285
Thyroid function, growth hormone deficiency and, 554
human immunodeficiency virus infection and, 755–757
hypothalamic amenorrhea and, 615–616, 618
in stress response, 707, 715, 720–721
indices of, **415–427**
Achilles reflex time as, 424
basal metabolic rate as, 424–425
clinical symptom scales, for hyperthyroidism, 416–419
for hypothyroidism, 419–420
lipid metabolism as, 424
muscle function as, 422–423
myocyte enzymes as, 422–423
organ-specific measures, 420–422
range of, 415–416
serum enzymes as, 423
serum proteins as, 423
Thyroid gland, adult anatomy of, 292
developmental abnormalities of, 304
scintigraphy of, 301–304, 344
ultrasonography of, 344
embryology of, 291–292
enlargement of. See *Goiters.*
fine-needle aspiration biopsy of, **361–400**. See also *Fine-needle aspiration biopsy (FNAB).*
imaging techniques for, 339–340
infections of. See *Thyroiditis.*
scintigraphy of, radioiodine uptake and, **291–313**. See also *Thyroid scintiscanning.*
ultrasound of, **339–360**. See also *Thyroid ultrasonography.*
Thyroid hormone-binding autoantibodies. See *Thyroid autoantibodies.*
Thyroid hormone-binding ratio (THBR), free thyroid hormone measurement by, 266, 270, 272
estimation of free T_4 concentration for, 271–276
Thyroid hormone suppression therapy, for thyroid lesion diagnosis, 253, 257–258, 260, 392–393
scintigraphy with, 296, 308, 310, 312
thyroglobulin measurement with, 443
Thyroid hormone therapy. See also *specific hormone.*
for thyroid carcinoma, thyroglobulin measurement and, 438–439

Thyroid hormone therapy *(Continued)*
free thyroid hormone levels with, 278
monitoring of, 247
clinical symptom scale for, 420
thyroid-stimulating hormone limitations in, 253–254
thyroid scintiscan interference by, 294, 299–300
with human immunodeficiency virus infection, 756–757
Thyroid hormones, measurement of. See *Free thyroid hormone measurement.*
regulatory mechanisms of, thyroid-stimulating hormone in, 245–246, 248
resistance to, gene mutations in, 248
Thyroid incidentalomas, fine-needle aspiration biopsy of, 364–365
ultrasonography of, 354
Thyroid lymphoma, cytologic diagnosis of, 372
goiter versus, 402–403
computed tomography of, 407
management of, 374–375
Thyroid neoplasia, benign, 371, 375
cytologic diagnosis of, 371, 375
genetic markers of, **493–513**. See also *specific gene.*
anaplastic, 504
follicular epithelium, 502–507
hereditary medullary, 493–501
papillary, 502–503
RET proto-oncogene as, 493–503, 505
sporadic medullary, 501
malignant. See *Thyroid carcinoma.*
Thyroid nodules, benign, management of, 375–382
ultrasonography of, 352–354
fine-needle aspiration biopsy of, for management guidance, 373–389, 506
indications for, 306–308, 310, 312
palpable versus nonpalpable, 363–365
ultrasound-guided, 353–354, 362, 367, 391
imaging of, 411–413
incidental, fine-needle aspiration biopsy of, 364–365
ultrasonography of, 354
malignant. See *Thyroid carcinoma.*
scintigraphy of, 352
as developmental abnormalities, 302–303
as goiter, 306–308, 310
suspicious, management of, 382–389, 394
thyroglobulin measurements in, 453–454
thyroxine suppression testing for, 392–393
ultrasonography of, 352–354
European versus American, 343–344, 352–354
Thyroid peroxidase (TPO) antibodies, as thyroid lesion marker, 388
assay detection of, 320
clinical applications of, 321–329
immunobiology of, 315, 318
in thyroid-stimulating hormone measurements, 250, 253, 256
pregnancy impact of, 326–327
testing indications for, 330
Thyroid scintiscanning, noniodine uptake and, 477–485
radioiodine uptake and, **291–313**
adult anatomy for, 292
clinical interpretation of, 297–300
decreased uptake causes, 297–300
elevated uptake causes, 297, 299
hyperthyroidism in, 298–299
clinical utility of, 301–312
in Hashimoto's thyroiditis, 299–300, 304–305, 312
in hyperthyroidism, 304–306
in nodule evaluation, 306–308, 310
in normal thyroid, 301–302, 304
in thyroid cancer, 310, 312
with descent and development abnormalities, 301–302, 304
contraindications for, 294
embryology for, 291–292
abnormalities with, 301–304
indications for, 300
measurement of, 293–297
methodology for, 294
normal ranges for, 296
patient preparation for, 294
principles of, 293–294
technique for, 295–296
variants of, 296–297
perchlorate discharge test with, 296–297
pertechnetate uptake test with, 293, 297
radiopharmaceuticals used for, 292–293
choice of, 300–301
for metastatic cancer, 469–475, 488
substances interfering with, 294, 299
suppression testing with, 296, 308, 310, 312
technical considerations of, 301
thyroglobulin level discordance with after hormone withdrawal, 444–447
somatostatin receptor, for metastatic cancer, 475, 482–483
Thyroid-stimulating antibodies (TSAb), clinical applications of, 321–329
immunobiology of, 318–319
testing indications for, 330
Thyroid-stimulating hormone (TSH), clinical, metabolic, and organ-specific indices of, 415–425
free T_4 relationship with, 284–285

human immunodeficiency virus infection and, 756
pituitary-thyroid axis assessment with, 254–256
regulatory mechanisms of, 245–246
serum measurement for thyroid function, **245–264**
appropriate peripheral and central action reflection with, 246–248
clinical utility of, 251–256
diurnal and seasonal variability in, 250
drugs affecting, 255–256
during pregnancy, 276–277
evolution of assays in, 245–246, 249–251, 255
normal range of, 250
pulsatile secretion in, 250
thyrotropin-releasing hormone stimulation tests for, 251
stimulation of, for thyroid cancer isotope imaging, 472–473, 485, 487–488
suppression testing of, for thyroid lesions, 253, 257–258, 260
scintiscanning with, 296, 308, 310, 312
thyroglobulin measurement and, 438–439
thyroid disease screening and assessment with, 251–252
limitations of, 252–254
thyroid hormone action reflection with, uncertainty of, 246–248
owing to heterogeneity of T_3 receptors, 248
owing to heterogeneity of T_4 deiodinases, 246–247
owing to negative feedback threshold resetting, 248
Thyroid-stimulating hormone-binding inhibitor immunoglobulin (TBII), clinical applications of, 321–329
immunobiology of, 318–319
testing indications for, 330
Thyroid-stimulating hormone receptor antibodies (TSHR-Ab, TRAb), assay detection of, 320–321
clinical applications of, 321–329
immunobiology of, 315, 318–319
nomenclature of, 318–319
testing indications for, 330
Thyroid-stimulating hormone stimulation-blocking antibodies (TSBAb, TSHBAb), clinical applications of, 321–329
immunobiology of, 318–319
testing indications for, 330
Thyroid-stimulating immunoglobulins (TSI), clinical applications of, 321–329
immunobiology of, 318–319
Thyroid ultrasonography, **339–360**
background for, 340–342, 356
clinical utility of, 339–341, 356
Doppler techniques in, 341–342, 345
with disease, 347, 349, 353
European versus American applications of, 339, 342–344, 350, 352–356
for fine-needle aspiration biopsy, 353–354
for focal disease, 350–354
carcinoma followup, 354, 381
cysts, 350–352, 355
incidental lesions, 354
multinodular goiter, 350
preoperative assessment, 354
solitary solid nodules, 352–354
for generalized disease, 345–349
acute infectious thyroiditis, 347
chronic autoimmune thyroiditis, 345–346
Graves' disease, 346–349
hyperthyroidism, 348–349
simple diffuse goiter, 342–343, 345
subacute thyroiditis, 347–348
future directions for, 356
limitations of, 341
normal gland characteristics, 342–344
of developmental defects, 344
of fetal gland, 344–345
of Hashimoto's thyroiditis, 345–346
of thyroid cancer, 352–354
as followup, 354, 381
metastatic, 471, 484, 488
real-time technique, 341, 367
therapeutic, for cysts, 352, 355
percutaneous ethanol injection, 355–356
Thyroid volume, after percutaneous ethanol injection therapy, 355
magnetic resonance imaging of, 409
ultrasonography determination of, 343, 345
in subacute thyroiditis, 347–348
Thyroidectomy, for benign thyroid lesions, 376
for malignant thyroid lesions, 374–375
prophylactic medullary, 499
thyroglobulin measurement with, 441, 443
Thyroiditis, acute infectious, ultrasonography of, 347
autoimmune. See *Autoimmune thyroiditis.*
fine-needle aspiration biopsy for, 365, 375
Hashimoto's, scintigraphy of, 299–300, 304–305, 312
thyroid autoantibodies in, 315–316, 319–320
ultrasonography of, 345–346
lymphocytic chronic, fine-needle aspiration biopsy of, 365, 370

Thyroiditis *(Continued)*
postpartum, scintigraphy of, 297, 299, 305–306
thyroglobulin measurements in, 453
thyroid autoantibodies in, 326–327
silent, autoantibody assays in, 322
scintigraphy of, 297, 299, 305–306
subacute. See *Subacute thyroiditis.*
with human immunodeficiency virus infection, 755
Thyrotoxicosis, clinical symptom scales for, 416
fine-needle aspiration biopsy for, 363
free thyroid hormone levels with, 278
in Graves' disease, autoantibody assays for, 321–322
testing for, thyroid-stimulating hormone limitations in, 253, 255
Thyrotoxicosis factitia, thyroglobulin measurements in, 452–453
Thyrotropin. See *Thyroid-stimulating hormone (TSH).*
Thyrotropin-releasing hormone (TRH), changes with aging, 634
in stress response, 707, 715
prolactin secretion and, 586–587
stimulation tests of, for thyroid-stimulating hormone measurement, 251, 255
with human immunodeficiency virus infection, 756
Thyroxine (T_4), clinical, metabolic, and organ-specific indices of, 415–425
in free thyroid hormone measurement, **265–289**
binding proteins in, 265–269
concentration estimation of, commercial methods for, 271–273
evaluation of methods, 274–276
validity impairment factors in, 273–275
critical illness and, 281–283
during replacement therapy, 278
evolution of assays for, 265–267, 269–270, 285
heparin artifact with, 280–281
hypothesis validity of, 267
hypothyroidism and, 278
in premature infants, 282–283
in special circumstances, 276–283
pregnancy and, 276–278
purpose of, 283–285
thyroid hormone binding competitors and, 278–280
thyroid hormone-binding ratio for, 266, 270
estimation of free T_4 concentration for, 271–276
thyroid-stimulating hormone relationship with, 284–285
thyrotoxicosis and, 278
regulatory mechanisms of, 245, 248
suppression testing of, for goiter scintigraphy, 310
for thyroid nodule diagnosis, 392–393
thyroid disease screening and assessment with, 252–255
thyroid-stimulating hormone reflection of action of, 246–248
Thyroxine-binding globulin (TBG), drugs competing with, 267–268, 276
free thyroid hormone impact of, 278–280
in free thyroid hormone measurement, 265–267
acquired changes in, 267–268
binding competitors impact on, 276, 278–280
during pregnancy, 276–277
with thyrotoxicosis, 278
Thyroxine-binding prealbumin. See *Transthyretin (TTR).*
Thyroxine deiodinases, thyroid-stimulating hormone levels reflection of, 246–248
Ticlopidine, for platelet inhibition, in type 2 diabetes, 1024
Tissue plasminogen activator (tPA), in type 2 diabetes, 1013–1014
Tissue staining, for fine-needle aspiration biopsy, of thyroid gland, 367–369
for thyroglobulin measurement, 450–451
TNX gene, in 21-hydroxylase deficiency, 37
Total risk-factor burden, in diabetes mellitus, coronary heart disease and, 873–874
insulin therapy and, 939–940
oral antihyperglycemic agents and, 921–922
Trachea, displacement of, with substernal goiter, 402, 407, 409, 413
Transsphenoidal surgery, for prolactinomas, 592–593
Transthyretin (TTR), in free thyroid hormone measurement, 265–266
acquired changes in, 268, 278
Tremor, as hyperthyroid symptom, 417
Tricyclic antidepressants, chronic stress response and, 719
Triglycerides, endothelium-derived vasodilation and, 987
in diabetes mellitus, NCEP guidelines for, 1002, 1008
in diabetic dyslipidemia, 1000
ADA categories of, 1001
ADA therapy thresholds for, 1002–1003
pharmacologic agents for, 872, 1005–1008
myocellular, in insulin resistance, 810, 812
Triiodothyronine (T_3), clinical, metabolic, and organ-specific indices of, 415–425

in free thyroid hormone measurement, **265–289**
binding proteins in, 265–269
during pregnancy, 276
evolution of assays for, 265–267, 269–270, 285
free T_4 concentration in, estimation methods of, 266, 270–276
in special circumstances, 276–283
role of, 283–284
thyroid-stimulating hormone relationship with, 284–285
hypothesis validity of, 267
purpose of, 285
thyroid hormone-binding ratio for, 266, 270
estimation of free T_4 concentration for, 271–276
regulatory mechanisms of, 245, 248
thyroid disease screening and assessment with, 252–255
thyroid-stimulating hormone reflection of action of, 248
Triiodothyronine receptors, thyroid-stimulating hormone levels reflection of, 248
Troglitazone, for diabetic hyperglycemia, dyslipidemia effects of, 1004
glycemic control with type 2 diabetes, 920
side effects of, 923, 926
with insulin therapy, 962–964
Trovert, for hypersomatotropism, 576
Tumor necrosis factor-a (TNF-a), in type 2 diabetes, 807
Turner's syndrome, estrogen concentrations with, 532–533
gonadal function with, 114
Tyrosine kinase activation, *RET* proto-oncogene mutations and, 494, 497–498

Ultrafiltration, for free thyroid hormone measurement, 267, 272
Ultrasonography, adrenal, for differential diagnosis, 45
basic principles of, 340–342
of thyroid, **339–360**. See also *Thyroid ultrasonography.*
pelvic, for genital ambiguity, 4
therapeutic, for thyroid cysts, 352, 355–356
Ultrasound-guided biopsy, of thyroid gland, 353–354, 362, 367, 391
United Kingdom Prospective Diabetes Study (UKPDS), 870, 909, 1040
insulin therapy and, 935–937, 941, 957–958
microvascular complications in, 845–846
Urinary output, arginine vasopressin role in, 672, 675–676
in diabetes insipidus, 676, 679–680
Urinary production rate by isotope dilution, for cortisol secretion rates, 195
Urine free cortisol, in Cushing's syndrome, 731–733
Urine osmolality, arginine vasopressin secretion and, 672–673
with diabetes insipidus, 680–682

Vagina, surgical reconstruction for, 144–150
dilatation procedures for adolescents, 150
gender identity and, 158–163
Vagus nerve, in stress response, 696–697, 700–701
in energy balance regulation, 777–778
Vascular endothelial growth factor (VEGF), as papillary thyroid cancer marker, 503
Vascular impairment, growth hormone deficiency and, 548
Vascular reactivity, in type 2 diabetes, exercise and, 895–897
thiazolidinediones effect on, 1041
Vascular thrombosis, in type 2 diabetes, 1011–1012
Vasoactive factors, in type 2 diabetes, endothelial production of, 985–987
Vasoactive intestinal peptide (VIP), prolactin secretion and, 586–587
Vasoactive tone, in type 2 diabetes, nitric oxide and, 985–987
Vasodilation, in type 2 diabetes, impaired endothelium-derived, 986–987
Ventricular function, as thyroid function index, 420–421
with cardiomyopathy, in diabetes mellitus, 1032–1036, 1040
Ventromedial hypothalamus (VMH), in energy balance regulation, 766–770, 775
Virilization. See *Genitalia virilization.*
Visceral adiposity, with stress response, 716
Vitrectomy, for diabetic retinopathy, 835–836
Voluntary energy expenditure, in energy balance regulation, 779

Water balance, antidiuretic hormone regulation of, 675–676
in adipsic hypernatremia, 685–687
in diabetes insipidus, 679–680

Water balance *(Continued)*
in syndrome of inappropriate antidiuretic hormone, 687–690
Weakness, as hyperthyroid symptom, 418
Weight changes, with congenital adrenal hyperplasia treatment, 200
during pregnancy, 200, 217
Weight gain, with insulin therapy, 941–942
with oral antihyperglycemic agents, 924, 926
Weight loss, fibrinolytic activity and, 1018
hypothalamic amenorrhea with, 612–617
nutrition for, 622–623
with hypothalamic obesity, 777–778
Wisconsin Epidemeologic Study of Diabetic Retinopathy (WESDR), 841
Wolffian ducts, in fetal sex differentiation, 139–140
Women, aging in, neuroendocrinology of, **631–646**
gonadal steroid feedback response, 639–642
hypothalamic function changes, 632–636
neuroendocrine changes, 632
ovarian changes, 632
overview of, 631–632, 642
pituitary function changes, 636–639
Women athletes, hypothalamic amenorrhea in, 612
etiology of, 615–617
neuroendocrine alterations with, 617–619
osteoporosis with, 619–622
treatment of, 622–623
reproductive stress response in, 714–715
WT–1 gene, in sex differentiation, 138–139

Y chromosome, sex-determining region of, 138–139